{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T07:55:46Z","timestamp":1772697346624,"version":"3.50.1"},"reference-count":211,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2021,8,14]],"date-time":"2021-08-14T00:00:00Z","timestamp":1628899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2021,8,14]],"date-time":"2021-08-14T00:00:00Z","timestamp":1628899200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100006601","name":"Ministero degli Affari Esteri e della Cooperazione Internazionale","doi-asserted-by":"publisher","award":["AID 8421"],"award-info":[{"award-number":["AID 8421"]}],"id":[{"id":"10.13039\/501100006601","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","award":["Special project on the Development of a Vaccine against HIV based on the Tat protein"],"award-info":[{"award-number":["Special project on the Development of a Vaccine against HIV based on the Tat protein"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","award":["RF-2011-02348970"],"award-info":[{"award-number":["RF-2011-02348970"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","award":["RF-2016-02364744"],"award-info":[{"award-number":["RF-2016-02364744"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","award":["Ricerca Corrente 2020"],"award-info":[{"award-number":["Ricerca Corrente 2020"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Virol"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1007\/s00705-021-05158-z","type":"journal-article","created":{"date-parts":[[2021,8,14]],"date-time":"2021-08-14T06:02:50Z","timestamp":1628920970000},"page":"2955-2974","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["New insights into pathogenesis point to HIV-1 Tat as a key vaccine target"],"prefix":"10.1007","volume":"166","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0545-8737","authenticated-orcid":false,"given":"Barbara","family":"Ensoli","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sonia","family":"Moretti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandra","family":"Borsetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Teresa","family":"Maggiorella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefano","family":"Butt\u00f2","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Orietta","family":"Picconi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonella","family":"Tripiciano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cecilia","family":"Sgadari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo","family":"Monini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aurelio","family":"Cafaro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,8,14]]},"reference":[{"key":"5158_CR1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0226803","volume":"15","author":"LP Zhao","year":"2020","unstructured":"Zhao LP, Fiore-Gartland A, Carpp LN, Cohen KW, Rouphael N, Fleurs L et al (2020) Landscapes of binding antibody and T-cell responses to pox-protein HIV vaccines in Thais and South Africans. PLoS One 15:e0226803. https:\/\/doi.org\/10.1371\/journal.pone.0226803","journal-title":"PLoS One"},{"key":"5158_CR2","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1038\/nrmicro3352","volume":"12","author":"NM Archin","year":"2014","unstructured":"Archin NM, Marsh Sung J, Garrido C, Soriano-Sarabia N, Margolis DM (2014) Eradicating HIV-1 infection: seeking to clear a persistent pathogen. Nat Rev Microbiol 12:750\u2013764. https:\/\/doi.org\/10.1038\/nrmicro3352","journal-title":"Nat Rev Microbiol"},{"key":"5158_CR3","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/j.molmed.2004.09.006","volume":"10","author":"K Lassen","year":"2004","unstructured":"Lassen K, Han Y, Zhou Y, Siliciano J, Siliciano RF (2004) The multifactorial nature of HIV-1 latency. Trends Mol Med 10:525\u2013531. https:\/\/doi.org\/10.1016\/j.molmed.2004.09.006","journal-title":"Trends Mol Med"},{"key":"5158_CR4","doi-asserted-by":"publisher","first-page":"3502","DOI":"10.1016\/j.vaccine.2013.05.018","volume":"31","author":"J Esparza","year":"2013","unstructured":"Esparza J (2013) A brief history of the global effort to develop a preventive HIV vaccine. Vaccine 31:3502\u201318. https:\/\/doi.org\/10.1016\/j.vaccine.2013.05.018","journal-title":"Vaccine"},{"key":"5158_CR5","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1128\/CVI.00131-10","volume":"17","author":"SA Plotkin","year":"2010","unstructured":"Plotkin SA (2010) Correlates of protection induced by vaccination. Clin Vaccine Immunol 17:1055\u201365. https:\/\/doi.org\/10.1128\/CVI.00131-10","journal-title":"Clin Vaccine Immunol"},{"key":"5158_CR6","doi-asserted-by":"publisher","first-page":"595","DOI":"10.3390\/v5020595","volume":"5","author":"LA Ara\u00fajo","year":"2013","unstructured":"Ara\u00fajo LA, Almeida SE (2013) HIV-1 diversity in the envelope glycoproteins: implications for viral entry inhibition. Viruses 5:595\u2013604. https:\/\/doi.org\/10.3390\/v5020595","journal-title":"Viruses"},{"issue":"8","key":"5158_CR7","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01843-17","volume":"92","author":"NL Yates","year":"2018","unstructured":"Yates NL, deCamp AC, Korber BT, Liao HX, Irene C, Pinter A, Peacock J, Harris LJ, Sawant S, Hraber P, Shen X, Rerks-Ngarm S, Pitisuttithum P, Nitayapan S, Berman PW, Robb ML, Pantaleo G, Zolla-Pazner S, Haynes BF, Alam SM, Montefiori DC, Tomaras GD (2018) HIV-1 Envelope Glycoproteins from Diverse Clades Differentiate Antibody Responses and Durability among Vaccinees. J Virol 92(8):e01843-17. https:\/\/doi.org\/10.1128\/JVI.01843-17","journal-title":"J Virol"},{"key":"5158_CR8","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1098\/rstb.2000.0637","volume":"355","author":"AJ McMichael","year":"2000","unstructured":"McMichael AJ, Callan M, Appay V, Hanke T, Ogg G, Rowland-Jones S (2000) The dynamics of the cellular immune response to HIV infection: implications for vaccination. Philos Trans R Soc Lond B Biol Sci 355:1007\u201311. https:\/\/doi.org\/10.1098\/rstb.2000.0637","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"key":"5158_CR9","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1038\/nri779","volume":"2","author":"A McMichael","year":"2002","unstructured":"McMichael A, Hanke T (2002) The quest for an AIDS vaccine: is the CD8+ T-cell approach feasible? Nat Rev Immunol 2:283\u201391. https:\/\/doi.org\/10.1038\/nri779","journal-title":"Nat Rev Immunol"},{"key":"5158_CR10","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/nri2674","volume":"10","author":"AJ McMichael","year":"2010","unstructured":"McMichael AJ, Borrow P, Tomaras GD, Goonetilleke N, Haynes BF (2010) The immune response during acute HIV-1 infection: clues for vaccine development. Nat Rev Immunol 10:11\u201323. https:\/\/doi.org\/10.1038\/nri2674","journal-title":"Nat Rev Immunol"},{"key":"5158_CR11","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1038\/nature11443","volume":"491","author":"PA Mudd","year":"2012","unstructured":"Mudd PA, Martins MA, Ericsen AJ, Tully DC, Power KA, Bean AT et al (2012) Vaccine-induced CD8+ T cells control AIDS virus replication. Nature 491:129\u201333. https:\/\/doi.org\/10.1038\/nature11443","journal-title":"Nature"},{"key":"5158_CR12","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0009015","volume":"5","author":"RA Koup","year":"2010","unstructured":"Koup RA, Roederer M, Lamoreaux L, Fischer J, Novik L, Nason MC et al (2010) Priming immunization with DNA augments immunogenicity of recombinant adenoviral vectors for both HIV-1 specific antibody and Tcell responses. PLoS One 5:e9015. https:\/\/doi.org\/10.1371\/journal.pone.0009015","journal-title":"PLoS One"},{"key":"5158_CR13","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1097\/COH.0b013e32833cfe4c","volume":"5","author":"DH Barouch","year":"2010","unstructured":"Barouch DH (2010) Novel adenovirus vector-based vaccines for HIV-1. Curr Opin HIV AIDS 5:386\u201390. https:\/\/doi.org\/10.1097\/COH.0b013e32833cfe4c","journal-title":"Curr Opin HIV AIDS"},{"key":"5158_CR14","doi-asserted-by":"publisher","first-page":"7097","DOI":"10.4049\/jimmunol.1002751","volume":"185","author":"AB Wilks","year":"2010","unstructured":"Wilks AB, Christian EC, Seaman MS, Sircar P, Carville A, Gomez CE, Esteban M, Pantaleo G, Barouch DH, Letvin NL, Permar SR (2010) Robust vaccine-elicited cellular immune responses in breast milk following systemic simian immunodeficiency virus DNA prime and live virus vector boost vaccination of lactating rhesus monkeys. J Immunol 185:7097\u2013106. https:\/\/doi.org\/10.4049\/jimmunol.1002751","journal-title":"J Immunol"},{"key":"5158_CR15","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1126\/science.318.5847.28","volume":"318","author":"J Cohen","year":"2007","unstructured":"Cohen J (2007) AIDS research. Promising AIDS vaccine\u2019s failure leaves field reeling. Science 318:28\u20139. https:\/\/doi.org\/10.1126\/science.318.5847.28","journal-title":"Science"},{"key":"5158_CR16","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1093\/infdis\/jis342","volume":"206","author":"A Duerr","year":"2012","unstructured":"Duerr A, Huang Y, Buchbinder S, Coombs RW, Sanchez J, del Rio C et al (2012) Extended follow-up confirms early vaccine-enhanced risk of HIV acquisition and demonstrates waning effect over time among participants in a randomized trial of recombinant adenovirus HIV vaccine (Step Study). J Infect Dis 206:258\u201366. https:\/\/doi.org\/10.1093\/infdis\/jis342","journal-title":"J Infect Dis"},{"key":"5158_CR17","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1016\/S0140-6736(08)61591-3","volume":"372","author":"SP Buchbinder","year":"2008","unstructured":"Buchbinder SP, Mehrotra DV, Duerr A, Fitzgerald DW, Mogg R, Li D et al (2008) Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 372:1881\u201393. https:\/\/doi.org\/10.1016\/S0140-6736(08)61591-3","journal-title":"Lancet"},{"key":"5158_CR18","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1056\/NEJMoa1310566","volume":"369","author":"SM Hammer","year":"2013","unstructured":"Hammer SM, Sobieszczyk ME, Janes H, Karuna ST, Mulligan MJ, Grove D, Koblin BA, Buchbinder SP, Keefer MC, Tomaras GD, Frahm N, Hural J, Anude C, Graham BS, Enama ME, Adams E, DeJesus E, Novak RM, Frank I, Bentley C, Ramirez S, Fu R, Koup RA, Mascola JR, Nabel GJ, Montefiori DC, Kublin J, McElrath MJ, Corey L, Gilbert PB (2013) N Engl J Med 369:2083\u201392. https:\/\/doi.org\/10.1056\/NEJMoa1310566","journal-title":"N Engl J Med"},{"key":"5158_CR19","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/S1473-3099(14)70020-9","volume":"14","author":"GE Gray","year":"2014","unstructured":"Gray GE, Moodie Z, Metch B, Gilbert PB, Bekker LG, Churchyard G, Nchabeleng M, Mlisana K, Laher F, Roux S, Mngadi K, Innes C, Mathebula M, Allen M, McElrath MJ, Robertson M, Kublin J, Corey L, HVTN 503, Phambili study team (2014) Recombinant adenovirus type 5 HIV gag\/pol\/nef vaccine in South Africa: unblinded, long-term follow-up of the phase 2b HVTN 503\/Phambili study. Lancet Infect Dis 14:388\u201396. https:\/\/doi.org\/10.1016\/S1473-3099(14)70020-9","journal-title":"Lancet Infect Dis"},{"key":"5158_CR20","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1097\/COH.0b013e32833d2d2b","volume":"5","author":"G Gray","year":"2010","unstructured":"Gray G, Buchbinder S, Duerr A (2010) Overview of STEP and Phambili trial results: two phase IIb test-of-concept studies investigating the efficacy of MRK adenovirus type 5 gag\/pol\/nef subtype B HIV vaccine. Curr Opin HIV AIDS 5:357\u201361. https:\/\/doi.org\/10.1097\/COH.0b013e32833d2d2b","journal-title":"Curr Opin HIV AIDS"},{"key":"5158_CR21","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1093\/infdis\/jix09","volume":"215","author":"S Rerks-Ngarm","year":"2017","unstructured":"Rerks-Ngarm S, Pitisuttithum P, Excler JL, Nitayaphan S, Kaewkungwal J, Premsri N, Kunasol P, Karasavvas N, Schuetz A, Ngauy V, Sinangil F, Dawson P, deCamp AC, Phogat S, Garunathan S, Tartaglia J, DiazGranados C, Ratto-Kim S, Pegu P, Eller M, Karnasuta C, Montefiori DC, Sawant S, Vandergrift N, Wills S, Tomaras GD, Robb ML, Michael NL, Kim JH, Vasan S, O\u2019Connell RJ, RV305 Study Team (2017) Randomized, Double-Blind Evaluation of Late Boost Strategies for\u00a0HIV-Uninfected\u00a0Vaccine\u00a0Recipients in the\u00a0RV144\u00a0HIV\u00a0Vaccine\u00a0Efficacy Trial. J Infect Dis. 215:1255\u20131263. https:\/\/doi.org\/10.1093\/infdis\/jix09","journal-title":"J Infect Dis."},{"key":"5158_CR22","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.virusres.2017.10.011","volume":"243","author":"Z Sun","year":"2018","unstructured":"Sun Z, Yan L, Tang J, Qian Q, Lenberg J, Zhu D, Liu W, Wu K, Wang Y, Lu S (2018) Brief introduction of current technologies in isolation of broadly neutralizing HIV-1 antibodies. Virus Res 243:75\u201382. https:\/\/doi.org\/10.1016\/j.virusres.2017.10.011","journal-title":"Virus Res"},{"key":"5158_CR23","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1111\/imr.12508","volume":"275","author":"G Kelsoe","year":"2017","unstructured":"Kelsoe G, Haynes BF (2017) Host controls of HIV broadly neutralizing antibody development. Immunol Rev 275:79\u201388. https:\/\/doi.org\/10.1111\/imr.12508","journal-title":"Immunol Rev"},{"key":"5158_CR24","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1003106","volume":"9","author":"S Hoot","year":"2013","unstructured":"Hoot S, McGuire AT, Cohen KW, Strong RK, Hangartner L, Klein F, Diskin R, Scheid JF, Sather DN, Burton DR, Stamatatos L (2013) Recombinant HIV envelope proteins fail to engage germline versions of anti-CD4bs bNAbs. PLoS Pathog 9:e1003106. https:\/\/doi.org\/10.1371\/journal.ppat.1003106","journal-title":"PLoS Pathog"},{"key":"5158_CR25","doi-asserted-by":"publisher","first-page":"2645","DOI":"10.1128\/JVI.03228-13","volume":"88","author":"AT McGuire","year":"2014","unstructured":"McGuire AT, Glenn JA, Lippy A, Stamatatos L (2014) Diverse recombinant HIV-1 Envs fail to activate B cells expressing the germline B cell receptors of the broadly neutralizing anti-HIV-1 antibodies PG9 and 447\u201352D. J Virol 88:2645\u201357. https:\/\/doi.org\/10.1128\/JVI.03228-13","journal-title":"J Virol"},{"key":"5158_CR26","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1111\/imr.12509","volume":"275","author":"M Bonsignori","year":"2017","unstructured":"Bonsignori M, Liao HX, Gao F, Williams WB, Alam SM, Montefiori DC, Haynes BF (2017) Antibody-virus co-evolution in HIV infection: paths for HIV vaccine development. Immunol Rev 275:145\u2013160. https:\/\/doi.org\/10.1111\/imr.12509","journal-title":"Immunol Rev"},{"key":"5158_CR27","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1097\/COH.0000000000000548","volume":"14","author":"AT McGuire","year":"2019","unstructured":"McGuire AT (2019) Targeting broadly neutralizing antibody precursors: a na\u00efve approach to vaccine design. Curr Opin HIV AIDS 14:294\u2013301. https:\/\/doi.org\/10.1097\/COH.0000000000000548","journal-title":"Curr Opin HIV AIDS"},{"key":"5158_CR28","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1146\/annurev-immunol-041015-055515","volume":"34","author":"DR Burton","year":"2016","unstructured":"Burton DR, Hangartner L (2016) Broadly Neutralizing Antibodies to HIV and Their Role in Vaccine Design. Annual Review of Immunology 34:635\u2013659. https:\/\/doi.org\/10.1146\/annurev-immunol-041015-055515","journal-title":"Annual Review of Immunology"},{"key":"5158_CR29","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1038\/nm.2089","volume":"16","author":"DH Barouch","year":"2010","unstructured":"Barouch DH, O\u2019Brien KL, Simmons NL, King SL, Abbink P, Maxfield LF, Sun YH, La Porte A, Riggs AM, Lynch DM, Clark SL, Backus K, Perry JR, Seaman MS, Carville A, Mansfield KG, Szinger JJ, Fischer W, Muldoon M, Korber B (2010) Mosaic\u00a0HIV-1 vaccines expand the breadth and depth of cellular immune responses in rhesus monkeys. Nat Med 16:319\u201323. https:\/\/doi.org\/10.1038\/nm.2089","journal-title":"Nat Med"},{"key":"5158_CR30","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1038\/nbt.3187","volume":"33","author":"L Lin","year":"2015","unstructured":"Lin L, Finak G, Ushey K, Seshadri C, Hawn TR, Frahm N, Scriba TJ, Mahomed H, Hanekom W, Bart PA, Pantaleo G, Tomaras GD, Rerks-Ngarm S, Kaewkungwal J, Nitayaphan S, Pitisuttithum P, Michael NL, Kim JH, Robb ML, O\u2019Connell RJ, Karasavvas N, Gilbert P, De Rosa C, S, McElrath MJ, Gottardo R, (2015) COMPASS identifies T-cell subsets correlated with clinical outcomes. Nat Biotechnol 33:610\u20136. https:\/\/doi.org\/10.1038\/nbt.3187","journal-title":"Nat Biotechnol"},{"key":"5158_CR31","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1080\/14760584.2019.1640117","volume":"18","author":"JL Excler","year":"2019","unstructured":"Excler JL, Kim JH (2019) Novel prime-boost vaccine strategies against\u00a0HIV-1. Expert Rev Vaccin 18:765\u2013779. https:\/\/doi.org\/10.1080\/14760584.2019.1640117","journal-title":"Expert Rev Vaccin"},{"key":"5158_CR32","doi-asserted-by":"publisher","first-page":"9039","DOI":"10.1128\/JVI.01013-06","volume":"80","author":"E Chertova","year":"2006","unstructured":"Chertova E, Chertov O, Coren LV, Roser JD, Trubey CM, Bess JW Jr, Sowder RC 2nd, Barsov E, Hood BL, Fisher RJ et al (2006) Proteomic and biochemical analysis of purified human immunodeficiency virus type 1 produced from infected monocyte-derived macrophages. J Virol 80:9039\u20139052. https:\/\/doi.org\/10.1128\/JVI.01013-06","journal-title":"J Virol"},{"key":"5158_CR33","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1093\/emboj\/16.6.1224","volume":"16","author":"D Harrich","year":"1997","unstructured":"Harrich D, Ulich C, Garc\u00eda-Mart\u00ednez LF, Gaynor RB (1997) Tat is required for efficient HIV-1 reverse transcription. EMBO J 16:1224\u20131235. https:\/\/doi.org\/10.1093\/emboj\/16.6.1224","journal-title":"EMBO J"},{"key":"5158_CR34","doi-asserted-by":"publisher","first-page":"2802","DOI":"10.1182\/blood-2004-06-2212","volume":"105","author":"S Marchi\u00f2","year":"2005","unstructured":"Marchi\u00f2 S, Alfano M, Primo L, Gramaglia D, Butini L, Gennero L, De Vivo E, Arap W, Giacca M, Pasqualini R et al (2005) Cell surface-associated Tat modulates HIV-1 infection and spreading through a specific interaction with gp120 viral envelope protein. Blood 105:2802\u20132811. https:\/\/doi.org\/10.1182\/blood-2004-06-2212","journal-title":"Blood"},{"key":"5158_CR35","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0048781","volume":"7","author":"P Monini","year":"2012","unstructured":"Monini P, Cafaro A, Srivastava IK, Moretti S, Sharma VA, Andreini C, Chiozzini C, Ferrantelli F, Cossut MR, Tripiciano A et al (2012) HIV-1 tat promotes integrin-mediated HIV transmission to dendritic cells by binding Env spikes and competes neutralization by anti-HIV antibodies. PLoS ONE 7:e48781. https:\/\/doi.org\/10.1371\/journal.pone.0048781","journal-title":"PLoS ONE"},{"key":"5158_CR36","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1126\/science.1061548","volume":"293","author":"Y Wu","year":"2001","unstructured":"Wu Y, Marsh JW (2001) Selective transcription and modulation of resting T cell activity by preintegrated HIV DNA. Science 293:1503\u20131506. https:\/\/doi.org\/10.1126\/science.1061548","journal-title":"Science"},{"key":"5158_CR37","first-page":"391","volume":"2","author":"CA Bohan","year":"1992","unstructured":"Bohan CA, Kashanchi F, Ensoli B, Buonaguro L, Boris-Lawrie KA, Brady JN (1992) Analysis of Tat transactivation of human immunodeficiency virus transcription in vitro. Gene Expr 2:391\u2013407","journal-title":"Gene Expr"},{"key":"5158_CR38","doi-asserted-by":"publisher","first-page":"9506","DOI":"10.1128\/JVI.00650-11","volume":"85","author":"AT Das","year":"2011","unstructured":"Das AT, Harwig A, Berkhout B (2011) The HIV-1 Tat protein has a versatile role in activating viral transcription. J Virol 85:9506\u20139516. https:\/\/doi.org\/10.1128\/JVI.00650-11","journal-title":"J Virol"},{"key":"5158_CR39","doi-asserted-by":"publisher","first-page":"4045","DOI":"10.1073\/pnas.88.9.4045","volume":"88","author":"MB Feinberg","year":"1991","unstructured":"Feinberg MB, Baltimore D, Frankel AD (1991) The role of Tat in the human immunodeficiency virus life cycle indicates a primary effect on transcriptional elongation. Proc Natl Acad Sci USA 88:4045\u20134049. https:\/\/doi.org\/10.1073\/pnas.88.9.4045","journal-title":"Proc Natl Acad Sci USA"},{"key":"5158_CR40","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.cell.2005.06.006","volume":"122","author":"LS Weinberger","year":"2005","unstructured":"Weinberger LS, Burnett JC, Toettcher JE, Arkin AP, Schaffer DV (2005) Stochastic Gene Expression in a Lentiviral Positive-Feedback Loop. Cell 122:169\u2013182. https:\/\/doi.org\/10.1016\/j.cell.2005.06.006","journal-title":"Cell"},{"key":"5158_CR41","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1016\/j.cell.2015.02.009","volume":"160","author":"BS Razooky","year":"2015","unstructured":"Razooky BS, Pai A, Aull K, Rouzine IM, Weinberger SL (2015) A Hardwired HIV Latency Program. Cell 160:990\u20131001. https:\/\/doi.org\/10.1016\/j.cell.2015.02.009","journal-title":"Cell"},{"key":"5158_CR42","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1126\/science.8493575","volume":"260","author":"TK Howcroft","year":"1993","unstructured":"Howcroft TK, Strebel K, Martin MA, Singer DS (1993) Repression of MHC class I gene promoter activity by two-exon Tat of HIV. Science 260:1320\u20131322. https:\/\/doi.org\/10.1126\/science.8493575","journal-title":"Science"},{"key":"5158_CR43","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/S1074-7613(00)80159-4","volume":"12","author":"S Kanazawa","year":"2000","unstructured":"Kanazawa S, Okamoto T, Peterlin BM (2000) Tat competes with CIITA for the binding to P-TEFb and blocks the expression of MHC class II genes in HIV infection. Immunity 12:61\u201370. https:\/\/doi.org\/10.1016\/S1074-7613(00)80159-4","journal-title":"Immunity"},{"key":"5158_CR44","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1038\/nm822","volume":"9","author":"E Izmailova","year":"2003","unstructured":"Izmailova E, Bertley FMN, Huang Q et al (2003) HIV-1 Tat reprograms immature dendritic cells to express chemoattractants for activated T cells and macrophages. Nat Med 9:191\u2013197. https:\/\/doi.org\/10.1038\/nm822","journal-title":"Nat Med"},{"key":"5158_CR45","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1128\/JVI.67.1.277-287.1993","volume":"67","author":"B Ensoli","year":"1993","unstructured":"Ensoli B, Buonaguro L, Barillari G, Fiorelli V, Gendelman R, Morgan RA, Wingfield P, Gallo RC (1993) Release, uptake, and effects of extracellular human immunodeficiency virus type 1 Tat protein on cell growth and viral transactivation. J Virol 67:277\u2013287. https:\/\/doi.org\/10.1128\/JVI.67.1.277-287.1993","journal-title":"J Virol"},{"key":"5158_CR46","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1097\/00002030-199712000-00006","volume":"11","author":"HC Chang","year":"1997","unstructured":"Chang HC, Samaniego F, Nair BC, Buonaguro L, Ensoli B (1997) HIV-1 Tat protein exits from cells via a leaderless secretory pathway and binds to extracellular matrix-associated heparan sulfate proteoglycans through its basic region. AIDS 11:1421\u20131431. https:\/\/doi.org\/10.1097\/00002030-199712000-00006","journal-title":"AIDS"},{"key":"5158_CR47","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1038\/emboj.2010.32","volume":"29","author":"F Rayne","year":"2010","unstructured":"Rayne F, Debaisieux S, Yezid H, Lin YL, Mettling C, Konate K, Chazal N, Arold ST, Pugni\u00e8re M, Sanchez F et al (2010) Phosphatidylinositol-(4,5)-bisphosphate enables efficient secretion of HIV-1 Tat by infected T-cells. EMBO J 29:1348\u20131362. https:\/\/doi.org\/10.1038\/emboj.2010.32","journal-title":"EMBO J"},{"key":"5158_CR48","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1038\/345084a0","volume":"345","author":"B Ensoli","year":"1990","unstructured":"Ensoli B, Barillari G, Salahuddin SZ, Gallo RC, Wong-Staal F (1990) Tat protein of HIV-1 stimulates growth of cells derived from Kaposi\u2019s sarcoma lesions of AIDS patients. Nature 345:84\u201386. https:\/\/doi.org\/10.1038\/345084a0","journal-title":"Nature"},{"key":"5158_CR49","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1038\/371674a0","volume":"371","author":"B Ensoli","year":"1994","unstructured":"Ensoli B, Gendelman R, Markham P, Fiorelli V, Colombini S, Raffeld M, Cafaro A, Chang HK, Brady JN, Gallo RC (1994) Synergy between basic fibroblast growth factor and HIV-1 Tat protein in induction of Kaposi\u2019s sarcoma. Nature 371:674\u2013680. https:\/\/doi.org\/10.1038\/371674a0","journal-title":"Nature"},{"key":"5158_CR50","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.90.17.7941","author":"G Barillari","year":"1993","unstructured":"Barillari G, Gendelman R, Gallo RC, Ensoli B (1993) The Tat protein of human immunodeficiency virus type 1, a growth factor for AIDS Kaposi sarcoma and cytokine-activated vascular cells, induces adhesion of the same cell types by using integrin receptors recognizing the RGD amino acid sequence. Proc Natl Acad Sci U S A. https:\/\/doi.org\/10.1073\/pnas.90.17.7941","journal-title":"Proc Natl Acad Sci U S A"},{"key":"5158_CR51","doi-asserted-by":"publisher","first-page":"13153","DOI":"10.1073\/pnas.95.22.13153","volume":"95","author":"A Albini","year":"1998","unstructured":"Albini A, Ferrini S, Benelli R, Sforzini S, Giunciuglio D, Aluigi MG, Proudfoot AE, Alouani S, Wells TN, Mariani G et al (1998) HIV-1 Tat protein mimicry of chemokines. Proc Natl Acad Sci USA 95:13153\u201313158. https:\/\/doi.org\/10.1073\/pnas.95.22.13153","journal-title":"Proc Natl Acad Sci USA"},{"key":"5158_CR52","doi-asserted-by":"publisher","first-page":"197","DOI":"10.4049\/jimmunol.168.1.197","volume":"168","author":"E Fanales-Belasio","year":"2002","unstructured":"Fanales-Belasio E, Moretti S, Nappi F, Barillari G, Micheletti F, Cafaro A, Ensoli B (2002) Native HIV-1 Tat protein targets monocyte-derived dendritic cells and enhances their maturation, function, and antigen-specific T cell responses. J Immunol 168:197\u2013206. https:\/\/doi.org\/10.4049\/jimmunol.168.1.197","journal-title":"J Immunol"},{"key":"5158_CR53","doi-asserted-by":"publisher","first-page":"E317","DOI":"10.3390\/ijms22010317","volume":"22","author":"A Cafaro","year":"2020","unstructured":"Cafaro A, Barillari G, Moretti S, Palladino C, Tripiciano A, Falchi M, Picconi O, Pavone Cossut MR, Campagna M, Arancio A, Sgadari C, Andreini C, Banci L, Monini P, Ensoli B (2020) HIV-1 Tat Protein Enters Dysfunctional Endothelial Cells via Integrins and Renders Them Permissive to Virus Replication. Int J Mol Sci 22:E317. https:\/\/doi.org\/10.3390\/ijms22010317","journal-title":"Int J Mol Sci"},{"key":"5158_CR54","doi-asserted-by":"publisher","first-page":"13588","DOI":"10.1073\/pnas.1308673110","volume":"110","author":"TP Johnson","year":"2013","unstructured":"Johnson TP, Patel K, Johnson KR, Maric D, Calabresi PA, Hasbun R, Nath A (2013) Induction of IL-17 and nonclassical T-cell activation by HIV-Tat protein. Proc Natl Acad Sci USA 110:13588\u201313593. https:\/\/doi.org\/10.1073\/pnas.1308673110","journal-title":"Proc Natl Acad Sci USA"},{"key":"5158_CR55","doi-asserted-by":"publisher","first-page":"8952","DOI":"10.1128\/JVI.72.11.8952-8960.1998","volume":"72","author":"L Huang","year":"1998","unstructured":"Huang L, Bosch I, Hofmann W, Sodroski J, Pardee AB (1998) Tat protein induces human immunodeficiency virus type 1 (HIV-1) coreceptors and promotes infection with both macrophage-tropic and T-lymphotropic HIV-1 strains. J. Virol 72:8952\u20138960. https:\/\/doi.org\/10.1128\/JVI.72.11.8952-8960.1998","journal-title":"J. Virol"},{"key":"5158_CR56","doi-asserted-by":"publisher","first-page":"11466","DOI":"10.1073\/pnas.97.21.11466","volume":"97","author":"H Xiao","year":"2000","unstructured":"Xiao H, Neuveut C, Tiffany HL et al (2000) Selective CXCR4 antagonism by Tat: Implications for\u00a0in vivo\u00a0expansion of coreceptor use by HIV-1. Proc Natl Acad Sci USA 97:11466\u201311471. https:\/\/doi.org\/10.1073\/pnas.97.21.11466","journal-title":"Proc Natl Acad Sci USA"},{"key":"5158_CR57","doi-asserted-by":"publisher","first-page":"8116","DOI":"10.1073\/pnas.94.15.8116","volume":"94","author":"CJ Li","year":"1997","unstructured":"Li CJ, Ueda Y, Shi B, Borodyansky L, Huang L, Li YZ, Pardee AB (1997) Tat protein induces self-perpetuating permissivity for productive HIV-1 infection. Proc Natl Acad Sci U S A 94:8116\u201320. https:\/\/doi.org\/10.1073\/pnas.94.15.8116","journal-title":"Proc Natl Acad Sci U S A"},{"key":"5158_CR58","doi-asserted-by":"publisher","first-page":"2888","DOI":"10.4049\/jimmunol.0711406","volume":"182","author":"E Fanales-Belasio","year":"2009","unstructured":"Fanales-Belasio E, Moretti S, Fiorelli V, Tripiciano A, Pavone Cossut MR, Scoglio A, Collacchi B, Nappi F, Macchia I, Bellino S et al (2009) HIV-1 Tat addresses dendritic cells to induce a predominant Th1-type adaptive immune response that appears prevalent in the asymptomatic stage of infection. J Immunol 182:2888\u20132897. https:\/\/doi.org\/10.4049\/jimmunol.0711406","journal-title":"J Immunol"},{"key":"5158_CR59","doi-asserted-by":"publisher","first-page":"7159","DOI":"10.1128\/JVI.66.12.7159-7167.1992","volume":"66","author":"L Buonaguro","year":"1992","unstructured":"Buonaguro L, Barillari G, Chang HK, Bohan CA, Kao V, Morgan R, Gallo RC, Ensoli B (1992) Effects of the human immunodeficiency virus type 1 Tat protein on the expression of inflammatory cytokines. J Virol 66:7159\u20137167. https:\/\/doi.org\/10.1128\/JVI.66.12.7159-7167.1992","journal-title":"J Virol"},{"key":"5158_CR60","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1084\/jem.179.3.961","volume":"179","author":"G Scala","year":"1994","unstructured":"Scala G, Ruocco MR, Ambrosino C, Mallardo M, Giordano V, Baldassarre F, Dragonetti E, Quinto I, Venuta S (1994) The expression of the interleukin 6 gene is induced by the human immunodeficiency virus 1 TAT protein. J Exp Med 179:961\u2013971. https:\/\/doi.org\/10.1084\/jem.179.3.961","journal-title":"J Exp Med"},{"key":"5158_CR61","doi-asserted-by":"publisher","first-page":"4077","DOI":"10.4049\/jimmunol.159.8.4077","volume":"159","author":"RM Lafrenie","year":"1997","unstructured":"Lafrenie RM, Wahl LM, Epstein JS, Yamada KM, Dhawan S (1997) Activation of monocytes by HIV-Tat treatment is mediated by cytokine expression. J Immunol 159:4077\u20134083","journal-title":"J Immunol"},{"key":"5158_CR62","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0129425","volume":"10","author":"N Ben Haij","year":"2015","unstructured":"Ben Haij N, Plan\u00e8s R, Leghmari K, Serrero M, Delobel P, Izopet J, BenMohamed L, Bahraoui E (2015) HIV-1 Tat Protein Induces Production of Proinflammatory Cytokines by Human Dendritic Cells and Monocytes\/Macrophages through Engagement of TLR4-MD2-CD14 Complex and Activation of NF-\u03baB Pathway. PLoS ONE 10:e0129425. https:\/\/doi.org\/10.1371\/journal.pone.0129425","journal-title":"PLoS ONE"},{"key":"5158_CR63","doi-asserted-by":"publisher","first-page":"5886","DOI":"10.1128\/JVI.00262-16","volume":"90","author":"R Plan\u00e8s","year":"2016","unstructured":"Plan\u00e8s R, Ben Haij N, Leghmari K, Serrero M, BenMohamed L, Bahraoui E (2016) HIV-1 Tat Protein Activates both the MyD88 and TRIF Pathways To Induce Tumor Necrosis Factor Alpha and Interleukin-10 in Human Monocytes. J Virol 90:5886\u20135898. https:\/\/doi.org\/10.1128\/JVI.00262-16","journal-title":"J Virol"},{"key":"5158_CR64","doi-asserted-by":"publisher","first-page":"2189","DOI":"10.1097\/QAD.0000000000000389","volume":"28","author":"C Chiozzini","year":"2014","unstructured":"Chiozzini C, Collacchi B, Nappi F, Bauer T, Arenaccio C, Tripiciano A, Longo O, Ensoli F, Cafaro A, Ensoli B et al (2014) Surface-bound Tat inhibits antigen-specific CD8+ T-cell activation in an integrin-dependent manner. AIDS 28:2189\u20132200. https:\/\/doi.org\/10.1097\/QAD.0000000000000389","journal-title":"AIDS"},{"key":"5158_CR65","doi-asserted-by":"publisher","first-page":"1868","DOI":"10.1093\/emboj\/cdg188","volume":"22","author":"A Jordan","year":"2003","unstructured":"Jordan A, Bisgrove B, Verdin E (2003) HIV reproducibly establishes latent infection after acute infection of T cells in vitro. EMBO J 22:1868\u201377. https:\/\/doi.org\/10.1093\/emboj\/cdg188","journal-title":"EMBO J"},{"key":"5158_CR66","doi-asserted-by":"publisher","first-page":"4716","DOI":"10.1128\/JVI.03478-12","volume":"87","author":"MS Dahabieh","year":"2013","unstructured":"Dahabieh MS, Ooms M, Simon V, Sadowski I (2013) A doubly fluorescent hiv-1 reporter shows that the majority of integrated HIV-1 is latent shortly after infection. J Virol 87:4716\u20134727. https:\/\/doi.org\/10.1128\/JVI.03478-12","journal-title":"J Virol"},{"key":"5158_CR67","doi-asserted-by":"publisher","first-page":"e1004955","DOI":"10.1371\/journal.ppat.1004955","volume":"11","author":"L Chavez","year":"2015","unstructured":"Chavez L, Calvanese V, Verdin E (2015) HIV latency is established directly and early in both resting and activated CD4 T cells. Plos Pathog 11:e1004955. https:\/\/doi.org\/10.1371\/journal.ppat.1004955","journal-title":"Plos Pathog"},{"key":"5158_CR68","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/j.cell.2013.09.039","volume":"155","author":"AD Weinberger","year":"2013","unstructured":"Weinberger AD, Weinberger LS (2013) Stochastic fate selection in HIV-infected patients. Cell 155:499\u201397. https:\/\/doi.org\/10.1016\/j.cell.2013.09.039","journal-title":"Cell"},{"key":"5158_CR69","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1084\/jem.20170193","volume":"214","author":"NN Hosmane","year":"2017","unstructured":"Hosmane NN, Kwon KJ, Bruner KM, Capoferri AA, Beg S, Rosenbloom DI, Keele BF, Ho YC, Siliciano JD, Siliciano RF (2017) Proliferation of latently infected CD4+ T cells carrying replication-competent HIV. J Exp Med 214:959\u2013972. https:\/\/doi.org\/10.1084\/jem.20170193","journal-title":"J Exp Med"},{"key":"5158_CR70","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1005745","volume":"11","author":"M Pinkevych","year":"2015","unstructured":"Pinkevych M, Cromer D, Tolstrup M, Grimm AJ, Cooper DA, Lewin SR, S\u00f8gaard OS, Rasmussen TA, Kent SJ, Kelleher AD (2015) Davenport MP (2015) HIV Reactivation from Latency after Treatment Interruption Occurs on Average Every 5\u20138 Days Implications for HIV Remission. PLoS Pathog 11:e1005000. https:\/\/doi.org\/10.1371\/journal.ppat.1005745","journal-title":"PLoS Pathog"},{"key":"5158_CR71","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.coviro.2019.03.004","volume":"38","author":"JM Zerbato","year":"2019","unstructured":"Zerbato JM, Purves HV, Lewin SR, Rasmussen TA (2019) Between a shock and a hard place: challenges and developments in HIV latency reversal. Curr Opin Virol 38:1\u20139. https:\/\/doi.org\/10.1016\/j.coviro.2019.03.004","journal-title":"Curr Opin Virol"},{"key":"5158_CR72","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.3390\/v12121443","volume":"12","author":"I Moranguinho","year":"2020","unstructured":"Moranguinho I, Valente ST (2020) Block-And-Lock: New Horizons for a Cure for HIV-1. Viruses 12:1443. https:\/\/doi.org\/10.3390\/v12121443","journal-title":"Viruses"},{"key":"5158_CR73","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1016\/j.immuni.2018.04.030","volume":"48","author":"S Sengupta","year":"2018","unstructured":"Sengupta S, Siliciano RF (2018) Targeting the Latent Reservoir for HIV-1. Immunity 48:872\u201395. https:\/\/doi.org\/10.1016\/j.immuni.2018.04.030","journal-title":"Immunity"},{"key":"5158_CR74","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1008791","volume":"16","author":"HA Aamer","year":"2020","unstructured":"Aamer HA, McClure J, Ko D et al (2020) Cells producing residual viremia during antiretroviral treatment appear to contribute to rebound viremia following interruption of treatment. Plos Pathog 16:e1008791. https:\/\/doi.org\/10.1371\/journal.ppat.1008791","journal-title":"Plos Pathog"},{"key":"5158_CR75","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1097\/QAD.0000000000001734","volume":"32","author":"F Nicoli","year":"2018","unstructured":"Nicoli F, Gallerani E, Sforza F, Finessi V, Chachage M, Geldmacher C, Cafaro A, Ensoli B, Caputo A, Gavioli R (2018) The HIV-1 Tat protein affects human CD4+ T-cell programming and activation, and favors the differentiation of na\u00efve CD4+ T cells. AIDS 32:575\u2013581. https:\/\/doi.org\/10.1097\/QAD.0000000000001734","journal-title":"AIDS"},{"key":"5158_CR76","doi-asserted-by":"publisher","first-page":"8227","DOI":"10.1128\/JVI.77.15.8227-8236.2003","volume":"77","author":"X Lin","year":"2003","unstructured":"Lin X, Irwin D, Kanazawa S, Huang L, Romeo J, Yen TS, Peterlin BM (2003) Transcriptional profiles of latent human immunodeficiency virus in infected individuals: Effects of Tat on the host and reservoir. J Virol 77:8227\u20138236. https:\/\/doi.org\/10.1128\/JVI.77.15.8227-8236.2003","journal-title":"J Virol"},{"key":"5158_CR77","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0013540","volume":"5","author":"B Ensoli","year":"2010","unstructured":"Ensoli B, Bellino S, Tripiciano A, Longo O, Francavilla V, Marcotullio S, Cafaro A, Picconi O, Paniccia G, Scoglio A et al (2010) Therapeutic immunization with HIV-1 Tat reduces immune activation and loss of regulatory T-cells and improves immune function in subjects on HAART. PLoS ONE 5:e13540. https:\/\/doi.org\/10.1371\/journal.pone.0013540","journal-title":"PLoS ONE"},{"key":"5158_CR78","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s12977-015-0151-y","volume":"12","author":"F Ensoli","year":"2015","unstructured":"Ensoli F, Cafaro A, Casabianca A, Tripiciano A, Bellino S, Longo O, Francavilla V, Picconi O, Sgadari C, Moretti S et al (2015) HIV-1 Tat immunization restores immune homeostasis and attacks the HAART-resistant blood HIV DNA: Results of a randomized phase II exploratory clinical trial. Retrovirology 12:33. https:\/\/doi.org\/10.1186\/s12977-015-0151-y","journal-title":"Retrovirology"},{"key":"5158_CR79","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1086\/382488","volume":"189","author":"TL Kieffer","year":"2004","unstructured":"Kieffer TL, Finucane MM, Nettles RE et al (2004) Genotypic analysis of HIV-1 drug resistance at the limit of detection: virus production without evolution in treated adults with undetectable HIV loads. J Infect Dis 189:1452\u201365. https:\/\/doi.org\/10.1086\/382488","journal-title":"J Infect Dis"},{"key":"5158_CR80","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1004010","volume":"10","author":"MF Kearney","year":"2014","unstructured":"Kearney MF, Spindler J, Shao W et al (2014) Lack of detectable hiv-1 molecular evolution during suppressive antiretroviral therapy. PLoS Pathog 10:e1004010. https:\/\/doi.org\/10.1371\/journal.ppat.1004010","journal-title":"PLoS Pathog"},{"key":"5158_CR81","doi-asserted-by":"publisher","unstructured":"Brodin J, Zanini F, Thebo L, et al. (2016) Establishment and stability of the latent HIV-1 DNA reservoir. eLife 5: e18889. https:\/\/doi.org\/10.7554\/eLife.18889","DOI":"10.7554\/eLife.18889"},{"key":"5158_CR82","doi-asserted-by":"publisher","first-page":"3827","DOI":"10.1172\/JCI94582","volume":"127","author":"GU Van Zyl","year":"2017","unstructured":"Van Zyl GU, Katusiime MG, Wiegand A et al (2017) No evidence of HIV replication in children on antiretroviral therapy. J Clin Invest 127:3827\u20133834. https:\/\/doi.org\/10.1172\/JCI94582","journal-title":"J Clin Invest"},{"key":"5158_CR83","doi-asserted-by":"publisher","first-page":"4629","DOI":"10.1172\/JCI126714","volume":"129","author":"WR McManus","year":"2019","unstructured":"McManus WR, Bale MJ, Spindler J et al (2019) HIV-1 in lymph nodes is maintained by cellular proliferation during antiretroviral therapy. J Clin Invest 129:4629\u20134642. https:\/\/doi.org\/10.1172\/JCI126714","journal-title":"J Clin Invest"},{"key":"5158_CR84","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaw5589","author":"MR Abrahams","year":"2019","unstructured":"Abrahams MR, Joseph SB, Garrett N et al (2019) The replication-competent HIV-1 latent reservoir is primarily established near the time of therapy initiation. Sci Transl Med. https:\/\/doi.org\/10.1126\/scitranslmed.aaw5589","journal-title":"Sci Transl Med"},{"key":"5158_CR85","doi-asserted-by":"publisher","first-page":"9625","DOI":"10.1128\/JVI.79.15.9625-9634.2005","volume":"79","author":"NH Tobin","year":"2005","unstructured":"Tobin NH, Learn GH, Holte SE, at al. (2005) Evidence that low-level viremias during effective highly active antiretroviral therapy result from two processes: expression of archival virus and replication of virus. J Virol 79:9625\u20139634. https:\/\/doi.org\/10.1128\/JVI.79.15.9625-9634.2005","journal-title":"J Virol"},{"key":"5158_CR86","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1038\/nm.2111","volume":"16","author":"MJ Buz\u00f3n","year":"2010","unstructured":"Buz\u00f3n MJ, Massanella M, Llibre JM et al (2010) HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects. Nat Med 16:460\u201365. https:\/\/doi.org\/10.1038\/nm.2111","journal-title":"Nat Med"},{"key":"5158_CR87","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1093\/infdis\/jit453","volume":"208","author":"H Hatano","year":"2013","unstructured":"Hatano H, Strain MC, Scherzer R (2013) Increase in 2\u2013Long Terminal Repeat Circles and Decrease in D-dimer After Raltegravir Intensification in Patients With Treated HIV Infection: A Randomized, Placebo-Controlled Trial. J Infect Dis 208:1436\u201342. https:\/\/doi.org\/10.1093\/infdis\/jit453","journal-title":"J Infect Dis"},{"key":"5158_CR88","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1073\/pnas.1318249111","volume":"111","author":"CV Fletcher","year":"2014","unstructured":"Fletcher CV, Staskus K, Wietgrefe SV et al (2014) Persistent HIV-1 replication in low drug concentration lymphatic tissues. Proc Natl Acad Sci USA 111:2307\u20132312. https:\/\/doi.org\/10.1073\/pnas.1318249111","journal-title":"Proc Natl Acad Sci USA"},{"key":"5158_CR89","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1038\/nature16933","volume":"530","author":"R Lorenzo-Redondo","year":"2016","unstructured":"Lorenzo-Redondo R, Fryer HR, Bedford T, Kim EY, Archer J, Pond SLK, Chung YS, Penugonda S, Chipman J, Fletcher CV, Schacker TW, Malim MH, Rambaut A, Haase AT, McLean AR, Wolinsky SM (2016) Persistent HIV-1 replication maintains the tissue reservoir during therapy. Nature 530:51\u201356. https:\/\/doi.org\/10.1038\/nature16933","journal-title":"Nature"},{"key":"5158_CR90","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1016\/j.immuni.2017.09.014","volume":"47","author":"L Shan","year":"2017","unstructured":"Shan L, Deng K, Gao H et al (2017) Transcriptional reprogramming during effector-to-memory transition renders CD4+ T cells permissive for latent HIV-1 infection. Immunity 47:766\u2013775. https:\/\/doi.org\/10.1016\/j.immuni.2017.09.014","journal-title":"Immunity"},{"key":"5158_CR91","doi-asserted-by":"publisher","first-page":"7626","DOI":"10.1074\/jbc.M112.408294","volume":"288","author":"MR L\u00f3pez-Huertas","year":"2013","unstructured":"L\u00f3pez-Huertas MR, Mateos E, S\u00e1nchez Del Cojo M, G\u00f3mez-Esquer F, D\u00edaz-Gil G, Rodr\u00edguez-Mora S, L\u00f3pez JA, Calvo E, L\u00f3pez-Campos G, Alcam\u00ed J et al (2013) The presence of HIV-1 Tat protein second exon delays fas protein-mediated apoptosis in CD4+ T lymphocytes: A potential mechanism for persistent viral production. J Biol Chem 288:7626\u20137644. https:\/\/doi.org\/10.1074\/jbc.M112.408294","journal-title":"J Biol Chem"},{"key":"5158_CR92","doi-asserted-by":"publisher","DOI":"10.1155\/2011\/452729","author":"C Sgadari","year":"2011","unstructured":"Sgadari C, Barillari G, Palladino C, Bellino S, Taddeo B, Toschi E, Ensoli B (2011) Fibroblast Growth Factor-2 and the HIV-1 Tat Protein Synergize in Promoting Bcl-2 Expression and Preventing Endothelial Cell Apoptosis: Implications for the Pathogenesis of AIDS-Associated Kaposi\u2019s Sarcoma. Int J Vasc Med. https:\/\/doi.org\/10.1155\/2011\/452729","journal-title":"Int J Vasc Med"},{"key":"5158_CR93","doi-asserted-by":"publisher","first-page":"3823","DOI":"10.1182\/blood.V86.10.3823.bloodjournal86103823","volume":"86","author":"G Zauli","year":"1995","unstructured":"Zauli G, Gibellini D, Caputo A, Bassini A, Negrini M, Monne M, Mazzoni M, Capitani S (1995) The human immunodeficiency virus type-1 Tat protein upregulates Bcl-2 gene expression in Jurkat T-cell lines and primary peripheral blood mononuclear cells. Blood 86:3823\u20133834","journal-title":"Blood"},{"key":"5158_CR94","doi-asserted-by":"publisher","first-page":"2542","DOI":"10.1172\/JCI13237","volume":"130","author":"Y Ren","year":"2020","unstructured":"Ren Y, Huang SH, Patel S, Alberto WDC, Magat D, Ahimovic D, Macedo AB, Durga R, Chan D, Zale E, Mota TM, Truong R, Rohwetter T, McCann CD, Kovacs CM, Benko E, Wimpelberg A, Cannon C, Hardy WD, Bosque A, Bollard CM, Jones RB (2020) BCL-2 antagonism sensitizes cytotoxic T cell-resistant HIV reservoirs to elimination ex vivo. J Clin Invest 130:2542\u20132559. https:\/\/doi.org\/10.1172\/JCI13237","journal-title":"J Clin Invest"},{"key":"5158_CR95","doi-asserted-by":"publisher","DOI":"10.3390\/v11030200","author":"S Zicari","year":"2019","unstructured":"Zicari S, Sessa L, Cotugno N, Ruggiero A, Morrocchi E, Concato C, Rocca S, Zangari P, Manno EC, Palma P (2019) Immune Activation, Inflammation, and Non-AIDS Co-Morbidities in HIV-Infected Patients under Long-Term ART. Viruses. https:\/\/doi.org\/10.3390\/v11030200","journal-title":"Viruses"},{"key":"5158_CR96","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1016\/S0140-6736(13)61809-7","volume":"382","author":"SG Deeks","year":"2013","unstructured":"Deeks SG, Lewin SR, Havlir DV (2013) The end of AIDS: HIV infection as a chronic disease. Lancet 382:1525\u201333. https:\/\/doi.org\/10.1016\/S0140-6736(13)61809-7","journal-title":"Lancet"},{"key":"5158_CR97","doi-asserted-by":"publisher","first-page":"81","DOI":"10.2174\/187152612798994939","volume":"12","author":"S Mediouni","year":"2012","unstructured":"Mediouni S, Darque A, Baillat G, Ravaux I, Dhiver C, Tissot-Dupont H, Mokhtari M, Moreau H, Tamalet C, Brunet C, Paul P, Dignat-George F, Stein A, Brouqui P, Spector SA, Campbell GR, Loret EP (2012) Antiretroviral therapy does not block the secretion of the human immunodeficiency virus tat protein. Infect Disord Drug Targets 12:81\u201386. https:\/\/doi.org\/10.2174\/187152612798994939","journal-title":"Infect Disord Drug Targets"},{"key":"5158_CR98","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0191613","volume":"13","author":"J Ferdin","year":"2018","unstructured":"Ferdin J, Gori\u010dar K, Dol\u017ean V, Plemenita\u0161 A, Martin JN, Peterlin BM, Deeks SG, Lenassi M (2018) Viral protein Nef is detected in plasma of half of HIV-infected adults with undetectable plasma HIV RNA. PLoS ONE 13:e0191613. https:\/\/doi.org\/10.1371\/journal.pone.0191613","journal-title":"PLoS ONE"},{"key":"5158_CR99","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1038\/nature10347","volume":"477","author":"A Sigal","year":"2011","unstructured":"Sigal A, Kim JT, Balazs AB, Dekel E, Mayo A, Milo R, Baltimore D (2011) Cell-to-cell spread of HIV permits ongoing replication despite antiretroviral therapy. Nature 477:95\u20138. https:\/\/doi.org\/10.1038\/nature10347","journal-title":"Nature"},{"key":"5158_CR100","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jiph.2014.08.003","volume":"8","author":"RNO Cobucci","year":"2015","unstructured":"Cobucci RNO, Lima PH, Carvalho de Souza P, Costa VV et al (2015) Assessing the impact of HAART on the incidence of defining and non-defining AIDS cancers among patients with HIV\/AIDS: a systematic review. J Infect Public Health 8:1\u201310. https:\/\/doi.org\/10.1016\/j.jiph.2014.08.003","journal-title":"J Infect Public Health"},{"key":"5158_CR101","first-page":"663","volume":"94","author":"G Barillari","year":"1999","unstructured":"Barillari G, Sgadari C, Fiorelli V, Samaniego F, Colombini S, Manzari V, Modesti A, Nair BC, Cafaro A, St\u00fcrzl M, Ensoli B (1999) The Tat protein of human immunodeficiency virus type-1 promotes vascular cell growth and locomotion by engaging the alpha5beta1 and alphavbeta3 integrins and by mobilizing sequestered basic fibroblast growth factor. Blood 94:663\u2013672","journal-title":"Blood"},{"key":"5158_CR102","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.4049\/jimmunol.163.4.1929","volume":"163","author":"G Barillari","year":"1999","unstructured":"Barillari G, Sgadari C, Palladino C, Gendelman R, Caputo A, Morris CB, Nair BC, Markham P, Nel A, St\u00fcrzl M, Ensoli B (1999) Inflammatory cytokines synergize with the HIV-1 Tat protein to promote angiogenesis and Kaposi\u2019s sarcoma via induction of basic fibroblast growth factor and the alpha v beta 3 integrin. J Immunol 163:1929\u20131935","journal-title":"J Immunol"},{"key":"5158_CR103","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1128\/cmr.15.2.310-326.2002","volume":"15","author":"G Barillari","year":"2002","unstructured":"Barillari G, Ensoli B (2002) Angiogenic effects of extracellular human immunodeficiency virus type 1 Tat protein and its role in the pathogenesis of AIDS-associated Kaposi\u2019s sarcoma. Clin Microbiol Rev 15:310\u201326. https:\/\/doi.org\/10.1128\/cmr.15.2.310-326.2002","journal-title":"Clin Microbiol Rev"},{"issue":"95","key":"5158_CR104","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1172\/JCI117849","volume":"1995","author":"V Fiorelli","year":"1995","unstructured":"Fiorelli V, Gendelman R, Samaniego F, Markham PD, Ensoli B (1995) Cytokines from activated T cells induce normal endothelial cells to acquire the phenotypic and functional features of AIDS-Kaposi\u2019s sarcoma spindle cells. J Clin Invest 1995(95):1723\u201334. https:\/\/doi.org\/10.1172\/JCI117849","journal-title":"J Clin Invest"},{"key":"5158_CR105","first-page":"956","volume":"91","author":"V Fiorelli","year":"1998","unstructured":"Fiorelli V, Gendelman R, Sirianni MC, Chang HK, Colombini S, Markham PD, Monini P, Sonnabend J, Pintus A, Gallo RC, Ensoli B (1998) gamma-Interferon produced by CD8+ T cells infiltrating Kaposi\u2019s sarcoma induces spindle cells with angiogenic phenotype and synergy with human immunodeficiency virus-1 Tat protein: an immune response to human herpesvirus-8 infection? Blood 91:956\u2013967","journal-title":"Blood"},{"key":"5158_CR106","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.4049\/jimmunol.162.2.1165","volume":"162","author":"V Fiorelli","year":"1999","unstructured":"Fiorelli V, Barillari G, Toschi E, Sgadari C, Monini P, St\u00fcrzl M, Ensoli B (1999) IFN-gamma induces endothelial cells to proliferate and to invade the extracellular matrix in response to the HIV-1 Tat protein: implications for AIDS-Kaposi\u2019s sarcoma pathogenesis. J Immunol 162:1165\u20131170","journal-title":"J Immunol"},{"key":"5158_CR107","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01280-19","volume":"94","author":"WS Yang","year":"2020","unstructured":"Yang WS, Lin TY, Chang L, Yeh WW, Huang SC, Chen TY, Hsieh YT, Chen ST, Li WC, Pan CC, Campbell M, Yen CH, Chen YA, Chang PC (2020) HIV-1 Tat interacts with a Kaposi\u2019s sarcoma-associated Herpesvirus reactivation-upregulated antiangiogenic long noncoding RNA, LINC00313, and antagonizes its function. J Virol 94:e01280-19. https:\/\/doi.org\/10.1128\/JVI.01280-19","journal-title":"J Virol"},{"key":"5158_CR108","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/978-3-030-44518-8_4","volume":"1263","author":"D Dandachi","year":"2020","unstructured":"Dandachi D, Mor\u00f3n F (2020) Effects of HIV on the tumor microenvironment. Adv Exp Med Biol 1263:45\u201354. https:\/\/doi.org\/10.1007\/978-3-030-44518-8_4","journal-title":"Adv Exp Med Biol"},{"key":"5158_CR109","doi-asserted-by":"publisher","first-page":"2401","DOI":"10.1128\/JVI.02024-06","volume":"81","author":"Y Zeng","year":"2007","unstructured":"Zeng Y, Zhang X, Huang Z, Cheng L, Yao S, Qin D, Chen X, Tang Q, Lv Z, Zhang L, Lu C (2007) Intracellular Tat of human immunodeficiency virus type 1 activates lytic cycle replication of Kaposi\u2019s sarcoma-associated herpesvirus: role of JAK\/STAT signaling. J Virol 81:2401\u201317. https:\/\/doi.org\/10.1128\/JVI.02024-06","journal-title":"J Virol"},{"key":"5158_CR110","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0053145","volume":"8","author":"F Zhou","year":"2013","unstructured":"Zhou F, Xue M, Qin D, Zhu X, Wang C, Zhu J, Hao T, Cheng L, Chen X, Bai Z, Feng N, Gao SJ, Chun LuC (2013) HIV-1 Tat promotes Kaposi\u2019s sarcoma-associated herpesvirus (KSHV) vIL-6-induced angiogenesis and tumorigenesis by regulating PI3K\/PTEN\/AKT\/GSK-3\u03b2 signaling pathway. PLoS One 8:e53145. https:\/\/doi.org\/10.1371\/journal.pone.0053145","journal-title":"PLoS One"},{"key":"5158_CR111","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1128\/MMBR.68.2.362-372.2004","volume":"68","author":"MS Longworth","year":"2004","unstructured":"Longworth MS, Laimins LA (2004) Pathogenesis of human papillomaviruses in differentiating epithelia. Microbiol Mol Biol Rev 68:362\u201372. https:\/\/doi.org\/10.1128\/MMBR.68.2.362-372.2004","journal-title":"Microbiol Mol Biol Rev"},{"key":"5158_CR112","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1159\/000150322","volume":"36","author":"ML Tornesello","year":"1993","unstructured":"Tornesello ML, Buonaguro FM, Beth-Giraldo E, Giraldo G (1993) Human immunodeficiency virus type 1 tat gene enhances human papillomavirus early gene expression. Intervirology 36:57\u201364. https:\/\/doi.org\/10.1159\/000150322","journal-title":"Intervirology"},{"key":"5158_CR113","doi-asserted-by":"publisher","first-page":"684","DOI":"10.4161\/cbt.5.6.2907","volume":"5","author":"J Nyagol","year":"2006","unstructured":"Nyagol J, Leucci E, Onnis A, De Falco G, Tigli C, Sanseverino F, Torriccelli M, Palummo N, Pacenti L, Santopietro R, Spina D, Gichangi P, Muchiri L, Lazzi S, Petraglia F, Leoncini L, Giordano A (2006) The effects of HIV-1 Tat protein on cell cycle during cervical carcinogenesis. Cancer Biol Ther 5:684\u201390. https:\/\/doi.org\/10.4161\/cbt.5.6.2907","journal-title":"Cancer Biol Ther"},{"key":"5158_CR114","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1016\/j.virol.2013.08.018","volume":"446","author":"SM Tugizov","year":"2013","unstructured":"Tugizov SM, Herrera R, Chin-Hong P, Veluppillai P, Greenspan D, Berry JM, Pilcher CD, Shiboski CH, Jay N, Rubin M, Chein A, Joel M (2013) HIV-associated disruption of mucosal epithelium facilitates paracellular penetration by human papillomavirus. Virology 446:378\u201388. https:\/\/doi.org\/10.1016\/j.virol.2013.08.018","journal-title":"Virology"},{"key":"5158_CR115","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1007\/s11904-014-0254-4","volume":"12","author":"C Brickman","year":"2015","unstructured":"Brickman C, Palefsky JM (2015) Human papillomavirus in the HIV-infected host: epidemiology and pathogenesis in the antiretroviral era. Curr HIV\/AIDS Rep 12:6\u201315. https:\/\/doi.org\/10.1007\/s11904-014-0254-4","journal-title":"Curr HIV\/AIDS Rep"},{"key":"5158_CR116","doi-asserted-by":"publisher","first-page":"2389","DOI":"10.3892\/ol.2016.4921","volume":"12","author":"G Barillari","year":"2016","unstructured":"Barillari G, Palladino C, Bacigalupo I, Leone P, Falchi M, Ensoli B (2016) Entrance of the Tat protein of HIV-1 into human uterine cervical carcinoma cells causes upregulation of HPV-E6 expression and a decrease in p53 protein levels. Oncol Lett 12:2389\u20132394. https:\/\/doi.org\/10.3892\/ol.2016.4921","journal-title":"Oncol Lett"},{"key":"5158_CR117","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/j.yexcr.2004.01.018","volume":"295","author":"E Colombrino","year":"2004","unstructured":"Colombrino E, Rossi E, Ballon G, Terrin L, Indraccolo S, Chieco-Bianchi L, De Rossi A (2004) Human immunodeficiency virus type 1 Tat protein modulates cell cycle and apoptosis in Epstein-Barr virus-immortalized B cells. Exp Cell Res 295:539\u201348. https:\/\/doi.org\/10.1016\/j.yexcr.2004.01.018","journal-title":"Exp Cell Res"},{"key":"5158_CR118","doi-asserted-by":"publisher","first-page":"2515","DOI":"10.1038\/leu.2017.106","volume":"31","author":"D Germini","year":"2017","unstructured":"Germini D, Tsfasman T, Klibi M, El-Amine R, Pichugin A, Iarovaia OV, Bilhou-Nabera C, Subra F, Bou Saada Y, Sukhanova A, Boutboul D, Rapha\u00ebl M, Wiels J, Razin SV, Bury-Mon\u00e9 S, Oksenhendler E, Lipinski M, Vassetzky YS (2017) HIV Tat induces a prolonged MYC relocalization next to IGH in circulating B-cells. Leukemia 31:2515\u20132522. https:\/\/doi.org\/10.1038\/leu.2017.106","journal-title":"Leukemia"},{"key":"5158_CR119","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1097\/COH.0000000000000333","volume":"12","author":"A Carbone","year":"2017","unstructured":"Carbone A, Volpi CC, Gualeni AV, Gloghini A (2017) Epstein-Barr virus associated lymphomas in people with HIV. Curr Opin HIV AIDS 12:39\u201346. https:\/\/doi.org\/10.1097\/COH.0000000000000333","journal-title":"Curr Opin HIV AIDS"},{"key":"5158_CR120","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.redox.2017.11.024","volume":"15","author":"R El-Amine","year":"2018","unstructured":"El-Amine R, Germini D, Zakharova VV, Tsfasman T, Sheval EV, Louzada RAN, Dupuy C, Bilhou-Nabera C, Hamade A, Najjar F, Oksenhendler E, Lipinski M, Chernyak BV, Vassetzky YS (2018) HIV-1 Tat protein induces DNA damage in human peripheral blood B-lymphocytes via mitochondrial ROS production. Redox Biol 15:97\u2013108. https:\/\/doi.org\/10.1016\/j.redox.2017.11.024","journal-title":"Redox Biol"},{"key":"5158_CR121","doi-asserted-by":"publisher","unstructured":"Wang X, Duan Z, Yu G, Fan M, Scharff MD (2018) Human immunodeficiency virus Tat protein aids V region somatic hypermutation in human B cells. mBio 9:e02315-17. https:\/\/doi.org\/10.1128\/mBio.02315-17","DOI":"10.1128\/mBio.02315-17"},{"key":"5158_CR122","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.28219","author":"FB Sall","year":"2019","unstructured":"Sall FB, El Amine R, Markozashvili D, Tsfasman T, Oksenhendler E, Lipinski M, Vassetzky Y, Germini D (2019) HIV-1 Tat protein induces aberrant activation of AICDA in human B-lymphocytes from peripheral blood. J Cell Physiol. https:\/\/doi.org\/10.1002\/jcp.28219","journal-title":"J Cell Physiol"},{"key":"5158_CR123","doi-asserted-by":"publisher","unstructured":"Duan M, Yao H, Hu G, Chen X, Lund AK, Buch S (2013) HIV Tat induces expression of ICAM-1 in HUVECs: implications for miR-221\/-222 in HIV-associated cardiomyopathy. PLoS One 8:e60170. https:\/\/doi.org\/10.1371\/journal.pone.0060170","DOI":"10.1371\/journal.pone.0060170"},{"key":"5158_CR124","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.carpath.2015.07.001","volume":"24","author":"T Wang","year":"2015","unstructured":"Wang T, Yi R, Green LA, Chelvanambi S, Seimetz M, Clauss M (2015) Increased cardiovascular disease risk in the HIV-positive population on ART: potential role of HIV-Nef and Tat. Cardiovasc Pathol 24:279\u201382. https:\/\/doi.org\/10.1016\/j.carpath.2015.07.001","journal-title":"Cardiovasc Pathol"},{"key":"5158_CR125","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1186\/s12967-018-1500-0","volume":"16","author":"Y Jiang","year":"2018","unstructured":"Jiang Y, Chai L, Blessing Fasae M, Bai Y (2018) The role of HIV Tat protein in HIV-related cardiovascular diseases. J Transl Med 16:121. https:\/\/doi.org\/10.1186\/s12967-018-1500-0","journal-title":"J Transl Med"},{"key":"5158_CR126","doi-asserted-by":"publisher","first-page":"61","DOI":"10.3389\/fcimb.2020.00061","volume":"10","author":"D Ajasin","year":"2020","unstructured":"Ajasin D, Eugenin EA (2020) HIV-1 Tat: Role in Bystander Toxicity. Front Cell Infect Microbiol 10:61. https:\/\/doi.org\/10.3389\/fcimb.2020.00061","journal-title":"Front Cell Infect Microbiol"},{"key":"5158_CR127","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1097\/QAD.0b013e328012c522","volume":"21","author":"S Doublier","year":"2007","unstructured":"Doublier S, Zennaro C, Spatola T, Lupia E, Bottelli A, Deregibus MC, Carraro M, Conaldi PG, Camussi G (2007) HIV-1 Tat reduces nephrin in human podocytes: a potential mechanism for enhanced glomerular permeability in HIV-associated nephropathy. AIDS 21:423\u201332. https:\/\/doi.org\/10.1097\/QAD.0b013e328012c522","journal-title":"AIDS"},{"key":"5158_CR128","doi-asserted-by":"publisher","unstructured":"Tang P, Das JR, Li J, Yu J, Ray PE (2020) An HIV-Tat inducible mouse model system of childhood HIV-associated nephropathy. Dis Model Mech 13:dmm045641. https:\/\/doi.org\/10.1242\/dmm.045641","DOI":"10.1242\/dmm.045641"},{"key":"5158_CR129","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.bbrc.2010.09.071","volume":"401","author":"D Gibellini","year":"2010","unstructured":"Gibellini D, De Crignis E, Ponti C, Borderi M, Cl\u00f2 A, Miserocchi A, Viale P, Re MC (2010) HIV-1 Tat protein enhances RANKL\/M-CSF-mediated osteoclast differentiation. Biochem Biophys Res Commun 401:429\u201334. https:\/\/doi.org\/10.1016\/j.bbrc.2010.09.071","journal-title":"Biochem Biophys Res Commun"},{"key":"5158_CR130","doi-asserted-by":"publisher","first-page":"19724","DOI":"10.7448\/IAS.17.4.19724","volume":"17","author":"N Chew","year":"2014","unstructured":"Chew N, Tan E, Li L, Lim R (2014) HIV-1 tat and rev upregulates osteoclast bone resorption. J Int AIDS Soc 17:19724. https:\/\/doi.org\/10.7448\/IAS.17.4.19724","journal-title":"J Int AIDS Soc"},{"key":"5158_CR131","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1111\/acel.12308","volume":"14","author":"C Beaupere","year":"2015","unstructured":"Beaupere C, Garcia M, Larghero J, F\u00e8ve B, Capeau J, Lagathu C (2015) The HIV proteins Tat and Nef promote human bone marrow mesenchymal stem cell senescence and alter osteoblastic differentiation. Aging Cell 14:534\u201346. https:\/\/doi.org\/10.1111\/acel.12308","journal-title":"Aging Cell"},{"key":"5158_CR132","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1053\/gast.2003.50056","volume":"124","author":"R Berni Canani","year":"2003","unstructured":"Berni Canani R, Cirillo P, Mallardo G, Buccigrossi V, Secondo A, Annunziato L, Bruzzese E, Albano F, Selvaggi F, Guarino A (2003) Effects of HIV-1 Tat protein on ion secretion and on cell proliferation in human intestinal epithelial cells. Gastroenterology 124:368\u201376. https:\/\/doi.org\/10.1053\/gast.2003.50056","journal-title":"Gastroenterology"},{"issue":"7","key":"5158_CR133","doi-asserted-by":"publisher","first-page":"7735","DOI":"10.1038\/s41598-017-05245-9","volume":"10","author":"G Esposito","year":"2017","unstructured":"Esposito G, Capoccia E, Gigli S, Pesce M, Bruzzese E, D\u2019Alessandro A, Cirillo C, di Cerbo A, Cuomo R, Seguella L, Steardo L, Sarnelli G (2017) HIV-1 Tat-induced diarrhea evokes an enteric glia-dependent neuroinflammatory response in the central nervous system. Sci Rep 10(7):7735. https:\/\/doi.org\/10.1038\/s41598-017-05245-9","journal-title":"Sci Rep"},{"key":"5158_CR134","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/s12974-018-1126-4","volume":"15","author":"G Sarnelli","year":"2018","unstructured":"Sarnelli G, Seguella L, Pesce M, Lu J, Gigli S, Bruzzese E, Lattanzi R, D\u2019Alessandro A, Cuomo R, Steardo L, Esposito G (2018) HIV-1 Tat-induced diarrhea is improved by the PPARalpha agonist, palmitoylethanolamide, by suppressing the activation of enteric glia. J Neuroinflammation 15:94. https:\/\/doi.org\/10.1186\/s12974-018-1126-4","journal-title":"J Neuroinflammation"},{"key":"5158_CR135","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1186\/1465-9921-12-103","volume":"12","author":"J Mermis","year":"2011","unstructured":"Mermis J, Gu H, Xue B, Li F, Tawfik O, Buch S, Bartolome S, O\u2019Brien-Ladner A, Dhillon NK (2011) Hypoxia-inducible factor-1\/platelet derived growth factor axis in HIV-associated pulmonary vascular remodeling. Respir Res 12:103. https:\/\/doi.org\/10.1186\/1465-9921-12-103","journal-title":"Respir Res"},{"key":"5158_CR136","doi-asserted-by":"publisher","first-page":"7984","DOI":"10.1038\/s41598-018-26095-z","volume":"8","author":"S Chinnapaiyan","year":"2018","unstructured":"Chinnapaiyan S, Dutta R, Bala J, Parira T, Agudelo M, Nair M, Unwalla HJ (2018) Cigarette smoke promotes HIV infection of primary bronchial epithelium and additively suppresses CFTR function. Sci Rep 8:7984. https:\/\/doi.org\/10.1038\/s41598-018-26095-z","journal-title":"Sci Rep"},{"key":"5158_CR137","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1152\/physrev.00039.2018","volume":"100","author":"SK Cribbs","year":"2020","unstructured":"Cribbs SK, Crothers K, Morris A (2020) Pathogenesis of HIV-related lung disease: immunity, infection, and inflammation. Physiol Rev 100:603\u2013632. https:\/\/doi.org\/10.1152\/physrev.00039.2018","journal-title":"Physiol Rev"},{"key":"5158_CR138","doi-asserted-by":"publisher","first-page":"3912","DOI":"10.1074\/jbc.M205107200","volume":"277","author":"X Liu","year":"2002","unstructured":"Liu X, Jana M, Dasgupta S, Koka S, He J, Wood C, Pahan K (2002) Human immunodeficiency virus type-1 (HIV-1) Tat induces nitric oxide synthase in human astroglia. J Biol Chem 277:3912\u201339319. https:\/\/doi.org\/10.1074\/jbc.M205107200","journal-title":"J Biol Chem"},{"key":"5158_CR139","doi-asserted-by":"publisher","first-page":"2629","DOI":"10.4049\/jimmunol.170.5.2629","volume":"170","author":"TA Kim","year":"2003","unstructured":"Kim TA, Avraham HK, Koh YH, Jiang S, Park IW, Avraham S (2003) HIV-1 Tat-mediated apoptosis in human brain microvascular endothelial cells. J Immunol 170:2629\u20132637. https:\/\/doi.org\/10.4049\/jimmunol.170.5.2629","journal-title":"J Immunol"},{"key":"5158_CR140","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1007\/s13365-017-0598-9","volume":"24","author":"D Langford","year":"2018","unstructured":"Langford D, Oh Kim B, Zou W, Fan Y, Rahimain P, Liu Y, He JJ (2018) Doxycycline-inducible and astrocyte-specific HIV-1 Tat transgenic mice (iTat) as an HIV\/neuroAIDS model. J Neurovirol 24:168\u2013179. https:\/\/doi.org\/10.1007\/s13365-017-0598-9","journal-title":"J Neurovirol"},{"key":"5158_CR141","doi-asserted-by":"publisher","first-page":"5079","DOI":"10.1007\/s00018-020-03561-4","volume":"77","author":"J Marino","year":"2020","unstructured":"Marino J, Maubert ME, Mele AR, Spector C, Wigdahl B, Nonnemacher MR (2020) Functional impact of HIV-1 Tat on cells of the CNS and its role in HAND. Cell Mol Life Sci 77:5079\u20135099. https:\/\/doi.org\/10.1007\/s00018-020-03561-4","journal-title":"Cell Mol Life Sci"},{"key":"5158_CR142","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0077746","volume":"8","author":"F Nicoli","year":"2013","unstructured":"Nicoli F, Finessi V, Sicurella M, Rizzotto L, Gallerani E, Destro F, Cafaro A, Marconi P, Caputo A, Ensoli B, Gavioli R (2013) The HIV-1 Tat protein induces the activation of CD8(+)T cells and affects in vivo the magnitude and kinetics of antiviral responses. PLoS One 8:e77746. https:\/\/doi.org\/10.1371\/journal.pone.0077746","journal-title":"PLoS One"},{"key":"5158_CR143","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.molimm.2012.12.003","volume":"54","author":"A Comandini","year":"2013","unstructured":"Comandini A, Naro C, Adamo R, Akbar AN, Lanna A, Bonmassar E, Franzese O (2013) Molecular mechanisms involved in HIV-1-Tat mediated inhibition of telomerase activity in human CD4(+) T lymphocytes. Mol Immunol 54:181\u201392. https:\/\/doi.org\/10.1016\/j.molimm.2012.12.003","journal-title":"Mol Immunol"},{"key":"5158_CR144","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1097\/QAD.0000000000000315","volume":"28","author":"F Sforza","year":"2014","unstructured":"Sforza F, Nicoli F, Gallerani E, Finessi V, Reali E, Cafaro A, Caputo A, Ensoli B, Gavioli R (2014) HIV-1 Tat affects the programming and functionality of human CD8(+) T cells by modulating the expression of T-box transcription factors. AIDS 28:1729\u20131738. https:\/\/doi.org\/10.1097\/QAD.0000000000000315","journal-title":"AIDS"},{"key":"5158_CR145","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.virol.2006.04.006","volume":"352","author":"MK White","year":"2006","unstructured":"White MK, Gorrill TS, Kamel Khalili K (2006) Reciprocal transactivation between HIV-1 and other human viruses. Virology 352:1\u201313. https:\/\/doi.org\/10.1016\/j.virol.2006.04.006","journal-title":"Virology"},{"issue":"10","key":"5158_CR146","doi-asserted-by":"publisher","first-page":"3019","DOI":"10.1002\/j.1460-2075.1989.tb08452.x","volume":"8","author":"B Ensoli","year":"1989","unstructured":"Ensoli B, Lusso P, Schachter F, Josephs SF, Rappaport J, Negro F, Gallo RC, Wong-Staal F (1989) Human herpes virus-6 increases HIV-1 expression in co-infected T cells via nuclear factors binding to the HIV-1 enhancer. EMBO J 8(10):3019\u20133027","journal-title":"EMBO J"},{"key":"5158_CR147","doi-asserted-by":"publisher","unstructured":"Wortman MJ, Krachmarov CP, Kim JH, Gordon RG, Chepenik LG, Brady JN, Gallia GL, Khalili K, Johnson EM (2000) Interaction of HIV-1 Tat with Puralpha in nuclei of human glial cells: characterization of RNA-mediated protein-protein binding. J Cell Biochem 77:65-74. https:\/\/doi.org\/10.1002\/(sici)1097-4644(20000401)77:1<65::aid-jcb7>3.0.co;2-u","DOI":"10.1002\/(sici)1097-4644(20000401)77:1<65::aid-jcb7>3.0.co;2-u"},{"key":"5158_CR148","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1002\/jcp.20375","volume":"204","author":"M Mischitelli","year":"2005","unstructured":"Mischitelli M, Fioriti D, Videtta M, Degener AM, Antinori A, Cinque P, Giordano A, Pietropaolo V (2005) Investigation on the role of cell transcriptional factor Sp1 and HIV-1 TAT protein in PML onset or development. J Cell Physiol 204:913\u20138. https:\/\/doi.org\/10.1002\/jcp.20375","journal-title":"J Cell Physiol"},{"key":"5158_CR149","doi-asserted-by":"publisher","first-page":"6937","DOI":"10.1128\/JVI.70.10.6937-6946.1996","volume":"70","author":"SL Schafer","year":"1996","unstructured":"Schafer SL, Vlach J, Pitha PM (1996) Cooperation between herpes simplex virus type 1-encoded ICP0 and Tat to support transcription of human immunodeficiency virus type 1 long terminal repeat in vivo can occur in the absence of the TAR binding site. J Virol 70:6937\u20136946. https:\/\/doi.org\/10.1128\/JVI.70.10.6937-6946.1996","journal-title":"J Virol"},{"key":"5158_CR150","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/s00430-015-0439-5","volume":"205","author":"D Karalic","year":"2016","unstructured":"Karalic D, Lazarevic I, Banko A, Cupic M, Jevtovic D, Jovanovic T (2016) Molecular characterization of BK virus in patients infected with human immunodeficiency virus. Med Microbiol Immunol 205:185\u201393. https:\/\/doi.org\/10.1007\/s00430-015-0439-5","journal-title":"Med Microbiol Immunol"},{"key":"5158_CR151","doi-asserted-by":"publisher","first-page":"5","DOI":"10.4103\/0974-2727.176228","volume":"8","author":"A Munawwar","year":"2016","unstructured":"Munawwar A, Singh S (2016) Human Herpesviruses as Copathogens of HIV Infection, Their Role in HIV Transmission, and Disease Progression. J Lab Physicians 8:5\u201318. https:\/\/doi.org\/10.4103\/0974-2727.176228","journal-title":"J Lab Physicians"},{"key":"5158_CR152","doi-asserted-by":"publisher","first-page":"3697","DOI":"10.1128\/IAI.60.9.3697-3703.1992","volume":"60","author":"AJ Crowle","year":"1992","unstructured":"Crowle AJ, Ross ER, Cohn DL, Gilden J, May MH (1992) Comparison of the abilities of Mycobacterium avium and Mycobacterium intracellulare to infect and multiply in cultured human macrophages from normal and human immunodeficiency virus-infected subjects. Infect Immun 60:3697\u20133703. https:\/\/doi.org\/10.1128\/IAI.60.9.3697-3703.1992","journal-title":"Infect Immun"},{"key":"5158_CR153","doi-asserted-by":"publisher","first-page":"2072","DOI":"10.4049\/jimmunol.153.5.2072","volume":"153","author":"M Denis","year":"1994","unstructured":"Denis M (1994) Tat protein from HIV-1 binds to Mycobacterium avium via a bacterial integrin. Effects on extracellular and intracellular growth. J Immunol 153:2072\u20132081","journal-title":"J Immunol"},{"key":"5158_CR154","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1111\/j.1574-695X.2001.tb00505.x","volume":"31","author":"H Kitaura","year":"2001","unstructured":"Kitaura H, Ohara N, Kobayashi K, Yamada T (2001) TNF-alpha-mediated activation of HIV-1 LTR in monocytoid cells by mycobacteria. FEMS Immunol Med Microbiol 31:97\u2013103. https:\/\/doi.org\/10.1111\/j.1574-695X.2001.tb00505.x","journal-title":"FEMS Immunol Med Microbiol"},{"key":"5158_CR155","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.lab.2004.05.012","volume":"144","author":"Z Toossi","year":"2004","unstructured":"Toossi Z, Wu M, Islam N, Teixeira-Johnson L, Hejal R, Aung H (2004) Transactivation of human immunodeficiency virus-1 in T-cells by Mycobacterium tuberculosis-infected mononuclear phagocytes. J Lab Clin Med 144:108\u2013115. https:\/\/doi.org\/10.1016\/j.lab.2004.05.012","journal-title":"J Lab Clin Med"},{"key":"5158_CR156","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1046\/j.1365-2567.2001.01328.x","volume":"104","author":"A Gruber","year":"2001","unstructured":"Gruber A, Lell CP, Speth C, Stoiber H, Lass-Florl C, Sonneborn A, Ernst JF, Dierich MP, W\u00fcrzner R (2001) Human immunodeficiency virus type 1 Tat binds to Candida albicans, inducing hyphae but augmenting phagocytosis in vitro. Immunology 104:455\u2013461. https:\/\/doi.org\/10.1046\/j.1365-2567.2001.01328.x","journal-title":"Immunology"},{"key":"5158_CR157","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1097\/QAD.0b013e32833ac6a0","volume":"24","author":"JC Li","year":"2010","unstructured":"Li JC, Yim HC, Lau ASY (2010) Role of HIV-1 Tat in AIDS pathogenesis: its effects on cytokine dysregulation and contributions to the pathogenesis of opportunistic infection. AIDS 24:1609\u201323. https:\/\/doi.org\/10.1097\/QAD.0b013e32833ac6a0","journal-title":"AIDS"},{"key":"5158_CR158","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.micpath.2015.11.005","volume":"90","author":"J Wei","year":"2016","unstructured":"Wei J, Zhang Y, Knapp PE, Zhao T (2016) HIV-1 Tat regulates the expression of the dcw operon and stimulates the proliferation of bacteria. Microb Pathog 90:34\u201340. https:\/\/doi.org\/10.1016\/j.micpath.2015.11.005","journal-title":"Microb Pathog"},{"key":"5158_CR159","doi-asserted-by":"publisher","unstructured":"de Carvalho Vivarini A, de Meirelles Santos Pereira R, Barreto-de-Souza V, Temerozo JR, Soares DC, Saraiva EM, Mattos Saliba A, Chequer Bou-Habib D, Gazos Lopes U (2015) HIV-1 Tat protein enhances the intracellular growth of Leishmania amazonensis via the ds-RNA induced protein PKR. Sci Rep 26:16777. https:\/\/doi.org\/10.1038\/srep16777","DOI":"10.1038\/srep16777"},{"key":"5158_CR160","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1086\/597387","volume":"199","author":"SP O\u2019Hara","year":"2009","unstructured":"O\u2019Hara SP, Small AJ, Gajdos GB, Badley AD, Chen XM, Larusso NF (2009) HIV-1 Tat protein suppresses cholangiocyte toll-like receptor 4 expression and defense against Cryptosporidium parvum. J Infect Dis 199:1195\u20131204. https:\/\/doi.org\/10.1086\/597387","journal-title":"J Infect Dis"},{"key":"5158_CR161","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.1016\/j.micinf.2005.07.016","volume":"7","author":"B Ensoli","year":"2005","unstructured":"Ensoli B, Cafaro A, Caputo A, Fiorelli V, Ensoli F, Gavioli R, Ferrantelli F, Cara A, Titti F, Magnani M (2005) Vaccines based on the native HIV Tat protein and on the combination of Tat and the structural HIV protein variant DeltaV2 Env. Microbes Infect 7:1392\u20139. https:\/\/doi.org\/10.1016\/j.micinf.2005.07.016","journal-title":"Microbes Infect"},{"key":"5158_CR162","doi-asserted-by":"publisher","first-page":"85","DOI":"10.4049\/jimmunol.176.1.85","volume":"176","author":"Z Hel","year":"2006","unstructured":"Hel Z, Tsai WP, Tryniszewska E, Nacsa J, Markham PD, Lewis MG, Pavlakis GN, Felber BK, Tartaglia J, Franchini G (2006) Improved vaccine protection from simian AIDS by the addition of nonstructural simian immunodeficiency virus genes. J Immunol 176:85\u201396. https:\/\/doi.org\/10.4049\/jimmunol.176.1.85","journal-title":"J Immunol"},{"key":"5158_CR163","doi-asserted-by":"publisher","first-page":"3333","DOI":"10.1128\/jvi.78.7.3333-3342.2004","volume":"78","author":"P Mooij","year":"2004","unstructured":"Mooij P, Nieuwenhuis IG, Knoop CJ, Doms RW, Bogers W, Ten Haaft P, Niphuis H, Koornstra W, Bieler K, K\u00f6stler J, Morein B, Cafaro A, Ensoli B, Wagner R, Heeney JL (2004) Qualitative T-helper responses to multiple viral antigens correlate with vaccine-induced immunity to simian\/human immunodeficiency virus infection. J Virol 78:3333\u201342. https:\/\/doi.org\/10.1128\/jvi.78.7.3333-3342.2004","journal-title":"J Virol"},{"key":"5158_CR164","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.virol.2005.07.016","volume":"342","author":"J Zhao","year":"2005","unstructured":"Zhao J, Voltan R, Peng B, Davis-Warren A, Kalyanaraman VS, Alvord W (2005) Enhanced cellular immunity to SIV Gag following co-administration of adenoviruses encoding wild-type or mutant HIV Tat and SIV Gag. Virology 342:1\u201312. https:\/\/doi.org\/10.1016\/j.virol.2005.07.016","journal-title":"Virology"},{"key":"5158_CR165","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1016\/j.vaccine.2007.11.040","volume":"26","author":"R Gavioli","year":"2008","unstructured":"Gavioli R, Cellini S, Castaldello A, Voltan R, Gallerani E, Gagliardoni F, Fortini C, Cofano EB, Triulzi C, Cafaro A et al (2008) The Tat protein broadens T cell responses directed to the HIV-1 antigens Gag and Env: Implications for the design of new vaccination strategies against AIDS. Vaccine 26:727\u2013737. https:\/\/doi.org\/10.1016\/j.vaccine.2007.11.040","journal-title":"Vaccine"},{"key":"5158_CR166","doi-asserted-by":"publisher","first-page":"3838","DOI":"10.4049\/jimmunol.173.6.3838","volume":"173","author":"R Gavioli","year":"2004","unstructured":"Gavioli R, Gallerani E, Fortini C, Fabris M, Bottoni A, Canella A, Bonaccorsi A, Marastoni M, Micheletti F, Cafaro A et al (2004) HIV-1 tat protein modulates the generation of cytotoxic T cell epitopes by modifying proteasome composition and enzymatic activity. J Immunol 173:3838\u20133843. https:\/\/doi.org\/10.4049\/jimmunol.173.6.3838","journal-title":"J Immunol"},{"key":"5158_CR167","doi-asserted-by":"publisher","first-page":"2067","DOI":"10.1038\/sj.gt.3302115","volume":"10","author":"JA Leifert","year":"2003","unstructured":"Leifert JA, Holler PD, Harkins S, Kranz DM, Whitton JL (2003) The cationic region from HIV tat enhances the cell-surface expression of epitope\/MHC class I complexes. Gene Ther 10:2067\u201373. https:\/\/doi.org\/10.1038\/sj.gt.3302115","journal-title":"Gene Ther"},{"key":"5158_CR168","doi-asserted-by":"publisher","first-page":"3105","DOI":"10.1074\/jbc.M509899200","volume":"281","author":"J Kittiworakarn","year":"2006","unstructured":"Kittiworakarn J, Lecoq A, Moine G, Thai R, Lajeunesse E, Drevet P, Vidaud C, M\u00e9nez A, L\u00e9onetti M (2006) HIV-1 Tat raises an adjuvant-free humoral immune response controlled by its core region and its ability to form cysteine-mediated oligomers. J Biol Chem 281:3105\u201315. https:\/\/doi.org\/10.1074\/jbc.M509899200","journal-title":"J Biol Chem"},{"key":"5158_CR169","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0100844","volume":"9","author":"M Sicurella","year":"2014","unstructured":"Sicurella M, Nicoli F, Gallerani E, Volpi I, Berto E, Finessi V, Destro F, Manservigi R, Cafaro A, Ensoli B, Caputo A, Gavioli R, Marconi PC (2014) An attenuated herpes simplex virus type 1 (HSV1) encoding the HIV-1 Tat protein protects mice from a deadly mucosal HSV1 challenge. PLoS One 9:e100844. https:\/\/doi.org\/10.1371\/journal.pone.0100844","journal-title":"PLoS One"},{"key":"5158_CR170","doi-asserted-by":"publisher","first-page":"2216","DOI":"10.1016\/j.vaccine.2016.03.022","volume":"34","author":"F Nicoli","year":"2016","unstructured":"Nicoli F, Gallerani E, Skarlis C, Sicurella M, Cafaro A, Ensoli B, Caputo A, Marconi PC, Gavioli R (2016) Systemic immunodominant CD8 responses with an effector-like phenotype are induced by intravaginal immunization with attenuated HSV vectors expressing HIV Tat and mediate protection against HSV infection. Vaccine 34:2216\u201324. https:\/\/doi.org\/10.1016\/j.vaccine.2016.03.022","journal-title":"Vaccine"},{"key":"5158_CR171","doi-asserted-by":"publisher","first-page":"274","DOI":"10.3390\/vaccines8020274","volume":"8","author":"F Nicoli","year":"2020","unstructured":"Nicoli F, Gallerani E, Sicurella M, Pacifico S, Cafaro A, Ensoli B, Marconi P, Caputo A, Gavioli R (2020) The Tat Protein of HIV-1 Prevents the Loss of HSV-Specific Memory Adaptive Responses and Favors the Control of Viral Reactivation. Vaccines (Basel) 8:274. https:\/\/doi.org\/10.3390\/vaccines8020274","journal-title":"Vaccines (Basel)"},{"key":"5158_CR172","doi-asserted-by":"publisher","first-page":"3776","DOI":"10.1128\/JVI.03419-14","volume":"89","author":"AA Khan","year":"2015","unstructured":"Khan AA, Srivastava R, Spencer D, Garg S, Fremgen D, Vahed H, Lopes PP, Pham TT, Hewett C, Kuang J, Ong N, Huang L, Scarfone VM, Nesburn AB, Wechsler SL, BenMohamed L (2015) Phenotypic and functional characterization of herpes simplex virus glycoprotein B epitope-specific effector and memory CD8+ T cells from symptomatic and asymptomatic individuals with ocular herpes. J Virol 89:3776\u201392. https:\/\/doi.org\/10.1128\/JVI.03419-14","journal-title":"J Virol"},{"key":"5158_CR173","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.4049\/jimmunol.1402606","volume":"194","author":"R Srivastava","year":"2015","unstructured":"Srivastava R, Khan AA, Spencer D, Vahed H, Lopes PP, Thai NT, Wang C, Pham TT, Huang J, Scarfone VM, Nesburn AB, Wechsler SL, BenMohamed L (2015) HLA-A02:01-restricted epitopes identified from the herpes simplex virus tegument protein VP11\/12 preferentially recall polyfunctional effector memory CD8+ T cells from seropositive asymptomatic individuals and protect humanized HLA-A*02:01 transgenic mice against ocular herpes. J Immunol 194:2232\u201348. https:\/\/doi.org\/10.4049\/jimmunol.1402606","journal-title":"J Immunol"},{"key":"5158_CR174","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1186\/s12879-016-1724-7","volume":"16","author":"A Cafaro","year":"2016","unstructured":"Cafaro A, Piccaro G, Altavilla G, Gigantino V, Matarese G, Olivieri E, Ferrantelli F, Ensoli B, Palma C (2016) HIV-1 Tat protein vaccination in mice infected with Mycobacterium tuberculosis is safe, immunogenic and reduces bacterial lung pathology. BMC Infect Dis 16:442. https:\/\/doi.org\/10.1186\/s12879-016-1724-7","journal-title":"BMC Infect Dis"},{"key":"5158_CR175","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1086\/428909","volume":"191","author":"G Rezza","year":"2005","unstructured":"Rezza G, Fiorelli V, Dorrucci M, Ciccozzi M, Tripiciano A, Scoglio A, Collacchi B, Ruiz-Alvarez M, Giannetto C, Caputo A et al (2005) The presence of anti-Tat antibodies is predictive of long-term nonprogression to AIDS or severe immunodeficiency: Findings in a cohort of HIV-1 seroconverters. J Infect Dis 191:1321\u20131324. https:\/\/doi.org\/10.1086\/428909","journal-title":"J Infect Dis"},{"key":"5158_CR176","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1097\/00042560-199512000-00003","volume":"10","author":"MC Re","year":"1995","unstructured":"Re MC, Furlini G, Vignoli M, Ramazzotti E, Roderigo G, De Rosa V, Zauli G, Lolli S, Capitani S, La Placa M (1995) Effect of antibody to HIV-1 Tat protein on viral replication in vitro and progression of HIV-1 disease in vivo. J Acquir Immune Defic Syndr Hum Retrovirol 10:408\u2013416. https:\/\/doi.org\/10.1097\/00042560-199512000-00003","journal-title":"J Acquir Immune Defic Syndr Hum Retrovirol"},{"key":"5158_CR177","first-page":"282","volume":"1","author":"JF Zagury","year":"1998","unstructured":"Zagury JF, Sill A, Blattner W, Lachgar A, Le Buanec H, Richardson M, Rappaport J, Hendel H, Bizzini B, Gringeri A et al (1998) Antibodies to the HIV-1 Tat protein correlated with nonprogression to AIDS: A rationale for the use of Tat toxoid as an HIV-1 vaccine. J Hum Virol 1:282\u2013292","journal-title":"J Hum Virol"},{"key":"5158_CR178","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/S1386-6532(00)00189-X","volume":"21","author":"MC Re","year":"2001","unstructured":"Re MC, Vignoli M, Furlini G, Gibellini D, Colangeli V, Vitone F, La Placa M (2001) Antibodies against full-length Tat protein and some low-molecular-weight Tat-peptides correlate with low or undetectable viral load in HIV-1 seropositive patients. J Clin Virol 21:81\u201389. https:\/\/doi.org\/10.1016\/S1386-6532(00)00189-X","journal-title":"J Clin Virol"},{"key":"5158_CR179","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/S0753-3322(02)00327-X","volume":"57","author":"MW Richardson","year":"2003","unstructured":"Richardson MW, Mirchandani J, Duong J, Grimaldo S, Kocieda V, Hendel H, Khalili K, Zagury JF, Rappaport J (2003) Antibodies to Tat and Vpr in the GRIV cohort: Differential association with maintenance of long-term non-progression status in HIV-1 infection. Biomed Pharmacother 57:4\u201314. https:\/\/doi.org\/10.1016\/S0753-3322(02)00327-X","journal-title":"Biomed Pharmacother"},{"key":"5158_CR180","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/1742-4690-11-49","volume":"11","author":"S Bellino","year":"2014","unstructured":"Bellino S, Tripiciano A, Picconi O, Francavilla V, Longo O, Sgadari C, Paniccia G, Arancio A, Angarano G, Ladisa N et al (2014) The presence of anti-Tat antibodies in HIV-infected individuals is associated with containment of CD4+ T-cell decay and viral load, and with delay of disease progression: Results of a 3-year cohort study. Retrovirology 11:49. https:\/\/doi.org\/10.1186\/1742-4690-11-49","journal-title":"Retrovirology"},{"key":"5158_CR181","doi-asserted-by":"publisher","first-page":"S13","DOI":"10.1517\/14712598.2015.1021328","volume":"15","author":"A Cafaro","year":"2015","unstructured":"Cafaro A, Tripiciano A, Sgadari C, Bellino S, Picconi O, Longo O, Francavilla V, Butt\u00f2 S, Titti F, Monini P et al (2015) Development of a novel AIDS vaccine: The HIV-1 transactivator of transcription protein vaccine. Expert Opin Biol Ther 15:S13\u2013S29. https:\/\/doi.org\/10.1517\/14712598.2015.1021328","journal-title":"Expert Opin Biol Ther"},{"key":"5158_CR182","doi-asserted-by":"publisher","first-page":"99","DOI":"10.3390\/vaccines7030099","volume":"7","author":"A Cafaro","year":"2019","unstructured":"Cafaro A, Tripiciano A, Picconi O, Sgadari C, Moretti S, Butt\u00f2 S, Monini P, Ensoli B (2019) Anti-Tat Immunity in HIV-1 Infection: Effects of Naturally Occurring and Vaccine-Induced Antibodies Against Tat on the Course of the Disease. Vaccines (Basel) 7:99. https:\/\/doi.org\/10.3390\/vaccines7030099","journal-title":"Vaccines (Basel)"},{"key":"5158_CR183","doi-asserted-by":"publisher","first-page":"5","DOI":"10.3389\/fimmu.2017.00005","volume":"8","author":"A Kulkarni","year":"2017","unstructured":"Kulkarni A, Kurle S, Shete A, Ghate M, Godbole S, Madhavi V, Kent J (2017) Indian Long-term Non-Progressors Show Broad ADCC Responses with Preferential Recognition of V3 Region of Envelope and a Region from Tat Protein. Front Immunol 8:5. https:\/\/doi.org\/10.3389\/fimmu.2017.00005","journal-title":"Front Immunol"},{"key":"5158_CR184","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1073\/pnas.98.4.1781","volume":"98","author":"MM Addo","year":"2001","unstructured":"Addo MM, Altfeld M, Rosenberg ES, Eldridge RL, Philips MN, Habeeb K, Khatri A, Brander C, Robbins GK, Mazzara GP et al (2001) HIV Controller Study Collaboration. The HIV-1 regulatory proteins Tat and Rev are frequently targeted by cytotoxic T lymphocytes derived from HIV-1-infected individuals. Proc Natl Acad Sci USA 98:1781\u20131786. https:\/\/doi.org\/10.1073\/pnas.98.4.1781","journal-title":"Proc Natl Acad Sci USA"},{"key":"5158_CR185","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1099\/0022-1317-78-8-1913","volume":"78","author":"CA Van Baalen","year":"1997","unstructured":"Van Baalen CA, Pontesilli O, Huisman RC, Geretti AM, Klein MR, de Wolf F, Miedema F, Gruters RA, Osterhaus AD (1997) Human immunodeficiency virus type 1 Rev- and Tat-specific cytotoxic T lymphocyte frequencies inversely correlate with rapid progression to AIDS. J Gen Virol 78:1913\u20131918. https:\/\/doi.org\/10.1099\/0022-1317-78-8-1913","journal-title":"J Gen Virol"},{"key":"5158_CR186","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1084\/jem.20040511","volume":"200","author":"NA Jones","year":"2004","unstructured":"Jones NA, Wei X, Flower DR, Wong M, Michor F, Saag MS, Hahn BH, Nowak MA, Shaw GM, Borrow P (2004) Determinants of human immunodeficiency virus type 1 escape from the primary CD8+ cytotoxic T lymphocyte response. J Exp Med 200:1243\u201356. https:\/\/doi.org\/10.1084\/jem.20040511","journal-title":"J Exp Med"},{"key":"5158_CR187","doi-asserted-by":"publisher","first-page":"3837","DOI":"10.4049\/jimmunol.171.7.3837","volume":"171","author":"J Cao","year":"2003","unstructured":"Cao J, McNevin J, Malhotra U et al (2003) Evolution of CD8+ T cell immunity and viral escape following acute HIV-1 infection. J Immunol 171:3837\u20133846. https:\/\/doi.org\/10.4049\/jimmunol.171.7.3837","journal-title":"J Immunol"},{"key":"5158_CR188","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2021.103306","volume":"66","author":"A Tripiciano","year":"2021","unstructured":"Tripiciano A, Picconi O, Moretti S, Sgadari C, Cafaro A, Francavilla V, Arancio A, Paniccia G, Campagna M, Pavone-Cossut MR, Sighinolfi L, Latini A, Mercurio VS, Pietro MD, Castelli F, Saracino A, Mussini C, Perri GD, Galli M, Nozza S, Ensoli F, Monini P, Ensoli B (2021) Anti-Tat immunity defines CD4+ T-cell dynamics in people living with HIV on long-term cART. EBioMedicine 66:103306. https:\/\/doi.org\/10.1016\/j.ebiom.2021.103306","journal-title":"EBioMedicine"},{"key":"5158_CR189","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1038\/9488","volume":"5","author":"A Cafaro","year":"1999","unstructured":"Cafaro A, Caputo A, Fracasso C, Maggiorella MT, Goletti D, Baroncelli S, Pace M, Sernicola L, Koanga-Mogtomo ML, Betti M et al (1999) Control of SHIV-89.6P-infection of cynomolgus monkeys by HIV-1 Tat protein vaccine. Nat Med 5:643\u2013650. https:\/\/doi.org\/10.1038\/9488","journal-title":"Nat Med"},{"key":"5158_CR190","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1034\/j.1600-0684.2000.290313.x","volume":"29","author":"A Cafaro","year":"2000","unstructured":"Cafaro A, Caputo A, Maggiorella MT, Baroncelli S, Fracasso C, Pace M, Borsetti A, Sernicola L, Negri DR, Ten Haaft P et al (2000) SHIV89.6P pathogenicity in cynomolgus monkeys and control of viral replication and disease onset by human immunodeficiency virus type 1 Tat vaccine. J Med Primatol 29:193\u2013208. https:\/\/doi.org\/10.1034\/j.1600-0684.2000.290313.x","journal-title":"J Med Primatol"},{"key":"5158_CR191","doi-asserted-by":"publisher","first-page":"2862","DOI":"10.1016\/S0264-410X(01)00002-0","volume":"19","author":"A Cafaro","year":"2001","unstructured":"Cafaro A, Titti F, Fracasso C, Maggiorella MT, Baroncelli S, Caputo A, Goletti D, Borsetti A, Pace M, Fanales-Belasio E et al (2001) Vaccination with DNA containing tat coding sequences and unmethylated CpG motifs protects cynomolgus monkeys upon infection with simian\/human immunodeficiency virus (SHIV89.6P). Vaccine 19:2862\u20132877. https:\/\/doi.org\/10.1016\/S0264-410X(01)00002-0","journal-title":"Vaccine"},{"key":"5158_CR192","doi-asserted-by":"publisher","first-page":"3258","DOI":"10.1016\/j.vaccine.2004.03.009","volume":"22","author":"MT Maggiorella","year":"2004","unstructured":"Maggiorella MT, Baroncelli S, Michelini Z, Fanales-Belasio E, Moretti S, Sernicola L, Cara A, Negri DR, Butt\u00f2 S, Fiorelli V et al (2004) Long-term protection against SHIV89.6P replication in HIV-1 Tat vaccinated cynomolgus monkeys. Vaccine 22:3258\u20133269. https:\/\/doi.org\/10.1016\/j.vaccine.2004.03.009","journal-title":"Vaccine"},{"key":"5158_CR193","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1089\/vim.2008.0082","volume":"22","author":"A Borsetti","year":"2009","unstructured":"Borsetti A, Baroncelli S, Maggiorella MT, Moretti S, Fanales-Belasio E, Sernicola L, Tripiciano A, Macchia I, Michelini Z, Belli R et al (2009) Containment of infection in tat vaccinated monkeys after rechallenge with a higher dose of SHIV89.6P(cy243). Viral Immunol 22:117\u2013124. https:\/\/doi.org\/10.1089\/vim.2008.0082","journal-title":"Viral Immunol"},{"key":"5158_CR194","doi-asserted-by":"publisher","first-page":"8953","DOI":"10.1128\/JVI.00377-10","volume":"84","author":"A Cafaro","year":"2010","unstructured":"Cafaro A, Bellino S, Titti F, Maggiorella MT, Sernicola L, Wiseman RW, Venzon D, Karl JA, O\u2019Connor D, Monini P et al (2010) Impact of viral dose and major histocompatibility complex class IB haplotype on viral outcome in mauritian cynomolgus monkeys vaccinated with Tat upon challenge with simian\/human immunodeficiency virus SHIV89.6P. J Virol 84:8953\u20138958. https:\/\/doi.org\/10.1128\/JVI.00377-10","journal-title":"J Virol"},{"key":"5158_CR195","doi-asserted-by":"publisher","first-page":"3414","DOI":"10.1128\/JVI.02453-06","volume":"81","author":"T Demberg","year":"2007","unstructured":"Demberg T, Florese RH, Heath MJ, Larsen K, Kalisz I, Kalyanaraman VS, Lee EM, Pal R, Venzon D, Grant R et al (2007) A replication-competent adenovirus-human immunodeficiency virus (Ad-HIV) tat and Ad-HIV env priming\/Tat and envelope protein boosting regimen elicits enhanced protective efficacy against simian\/human immunodeficiency virus SHIV89.6P challenge in rhesus macaques. J Virol 81:3414\u20133427. https:\/\/doi.org\/10.1128\/JVI.02453-06","journal-title":"J Virol"},{"key":"5158_CR196","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0022010","volume":"6","author":"SK Lakhashe","year":"2011","unstructured":"Lakhashe SK, Wang W, Siddappa NB, Hemashettar G, Polacino P, Hu SL, Villinger F, Else JG, Novembre FJ, Yoon JK, Lee SJ, Montefiori DC, Ruprecht RM, Rasmussen RA (2011) Vaccination against heterologous R5 clade C SHIV: prevention of infection and correlates of protection. PLoS One 6:e22010. https:\/\/doi.org\/10.1371\/journal.pone.0022010","journal-title":"PLoS One"},{"key":"5158_CR197","doi-asserted-by":"publisher","first-page":"4403","DOI":"10.1128\/JVI.02888-12","volume":"87","author":"BC Bachler","year":"2013","unstructured":"Bachler BC, Humbert M, Palikuqi B, Siddappa NB, Lakhashe SK, Rasmussen RA, Ruprecht RM (2013) Novel biopanning strategy to identify epitopes associated with vaccine protection. J Virol 87:4403\u20134416. https:\/\/doi.org\/10.1128\/JVI.02888-12","journal-title":"J Virol"},{"key":"5158_CR198","doi-asserted-by":"publisher","first-page":"2207","DOI":"10.1097\/QAD.0b013e32831392d4","volume":"22","author":"B Ensoli","year":"2008","unstructured":"Ensoli B, Fiorelli V, Ensoli F, Lazzarin A, Visintini R, Narciso P, Di Carlo A, Monini P, Magnani M, Garaci E (2008) The therapeutic phase I trial of the recombinant native HIV-1 Tat protein. AIDS 22:2207\u20132209. https:\/\/doi.org\/10.1097\/QAD.0b013e32831392d4","journal-title":"AIDS"},{"key":"5158_CR199","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.vaccine.2009.10.038","volume":"28","author":"B Ensoli","year":"2009","unstructured":"Ensoli B, Fiorelli V, Ensoli F, Lazzarin A, Visintini R, Narciso P, Di Carlo A, Tripiciano A, Longo O, Bellino S et al (2009) The preventive phase I trial with the HIV-1 Tat-based vaccine. Vaccine 28:371\u2013378. https:\/\/doi.org\/10.1016\/j.vaccine.2009.10.038","journal-title":"Vaccine"},{"key":"5158_CR200","doi-asserted-by":"publisher","first-page":"195","DOI":"10.2174\/157488709789957529","volume":"4","author":"S Bellino","year":"2009","unstructured":"Bellino S, Francavilla V, Longo O, Tripiciano A, Paniccia G, Arancio A, Fiorelli V, Scoglio A, Collacchi B, Campagna M et al (2009) Parallel conduction of the phase I preventive and therapeutic trials based on the Tat vaccine candidate. Rev Recent Clin Trials 4:195\u2013204. https:\/\/doi.org\/10.2174\/157488709789957529","journal-title":"Rev Recent Clin Trials"},{"key":"5158_CR201","doi-asserted-by":"publisher","first-page":"417","DOI":"10.3389\/fimmu.2014.00417","volume":"5","author":"B Ensoli","year":"2014","unstructured":"Ensoli B, Cafaro A, Monini P, Marcotullio S, Ensoli F (2014) Challenges in HIV vaccine research for treatment and prevention. Front Immunol 5:417. https:\/\/doi.org\/10.3389\/fimmu.2014.00417","journal-title":"Front Immunol"},{"key":"5158_CR202","doi-asserted-by":"publisher","first-page":"233","DOI":"10.3389\/fimmu.2019.00233","volume":"10","author":"C Sgadari","year":"2019","unstructured":"Sgadari C, Monini P, Tripiciano A, Picconi O, Casabianca A, Orlandi C, Moretti S, Francavilla V, Arancio A, Paniccia G et al (2019) Continued Decay of HIV Proviral DNA Upon Vaccination With HIV-1 Tat of Subjects on Long-Term ART: An 8-Year Follow-Up Study. Front Immunol 10:233. https:\/\/doi.org\/10.3389\/fimmu.2019.00233","journal-title":"Front Immunol"},{"key":"5158_CR203","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s12977-016-0261-1","volume":"13","author":"B Ensoli","year":"2016","unstructured":"Ensoli B, Nchabeleng M, Ensoli F, Tripiciano A, Bellino S, Picconi O, Sgadari C, Longo O, Tavoschi L, Joffe D, SMU-MeCRU study group et al (2016) HIV-Tat immunization induces cross-clade neutralizing antibodies and CD4(+) T cell increases in antiretroviral-treated South African volunteers: A randomized phase II clinical trial. Retrovirology 13:34. https:\/\/doi.org\/10.1186\/s12977-016-0261-1","journal-title":"Retrovirology"},{"issue":"9","key":"5158_CR204","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0184929","volume":"12","author":"M Ros\u00e1s-Umbert","year":"2017","unstructured":"Ros\u00e1s-Umbert M, Mothe B, Noguera-Julian M, Bellido R, Puertas MC, Carrillo J, Rodriguez C, Perez-Alvarez N, Cobars\u00ed P, Gomez CE, Esteban M, J\u00edmenez JL, Garc\u00eda F, Blanco J, Martinez-Picado J, Paredes R, Brander C (2017) Virological and immunological outcome of treatment interruption in HIV-1-infected subjects vaccinated with MVA-B. PLoS One 12(9):e0184929. https:\/\/doi.org\/10.1371\/journal.pone.0184929","journal-title":"PLoS One"},{"issue":"9","key":"5158_CR205","doi-asserted-by":"publisher","first-page":"4074","DOI":"10.1172\/JCI120549","volume":"128","author":"R Sharaf","year":"2018","unstructured":"Sharaf R, Lee GQ, Sun X, Etemad B, Aboukhater LM, Hu Z, Brumme ZL, Aga E, Bosch RJ, Wen Y, Namazi G, Gao C, Acosta EP, Gandhi RT, Jacobson JM, Skiest D, Margolis DM, Mitsuyasu R, Volberding P, Connick E, Kuritzkes DR, Lederman MM, Yu XG, Lichterfeld M, Li JZ (2018) HIV-1 proviral landscapes distinguish posttreatment controllers from noncontrollers. J Clin Invest 128(9):4074\u20134085. https:\/\/doi.org\/10.1172\/JCI120549","journal-title":"J Clin Invest"},{"issue":"Suppl 1","key":"5158_CR206","doi-asserted-by":"publisher","first-page":"S15","DOI":"10.1186\/1742-4690-3-S1-S15","volume":"3","author":"N Clumeck","year":"2006","unstructured":"Clumeck N, Hermans P, Zagury D, Le Buanec H, Burny A, Bizzini B, Gilliam B, Redfield R, Gallo R (2006) Neutralizing anti-Tat antibodies prolonged HAART interruption in vaccines in a prospective structured interruption study. Retrovirology 3(Suppl 1):S15. https:\/\/doi.org\/10.1186\/1742-4690-3-S1-S15","journal-title":"Retrovirology"},{"key":"5158_CR207","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s12977-016-0251-3","volume":"13","author":"EP Loret","year":"2016","unstructured":"Loret EP, Darque A, Jouve E, Loret EA, Nicolino-Brunet C, Morange S, Castanier E, Casanova J, Caloustian C, Bornet C, Coussirou J, Boussetta J, Couallier V, Blin O, Dussol B, Ravaux I (2016) Intradermal injection of a Tat Oyi-based therapeutic HIV vaccine reduces of 1.5 log copies\/mL the HIV RNA rebound median and no HIV DNA rebound following cART interruption in a phase I\/II randomized controlled clinical trial. Retrovirology 13:21. https:\/\/doi.org\/10.1186\/s12977-016-0251-3","journal-title":"Retrovirology"},{"issue":"1","key":"5158_CR208","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s12977-018-0455-9","volume":"15","author":"H Gruell","year":"2018","unstructured":"Gruell H, Klein F (2018) Antibody-mediated prevention and treatment of HIV-1 infection. Retrovirology 15(1):73. https:\/\/doi.org\/10.1186\/s12977-018-0455-9","journal-title":"Retrovirology"},{"issue":"2","key":"5158_CR209","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1128\/JVI.64.2.962-965.1990","volume":"64","author":"DA Brake","year":"1990","unstructured":"Brake DA, Goudsmit J, Krone WJ, Schammel P, Appleby N, Meloen RH, Debouck C (1990) Characterization of murine monoclonal antibodies to the tat protein from human immunodeficiency virus type 1. J Virol 64(2):962\u20135. https:\/\/doi.org\/10.1128\/JVI.64.2.962-965.1990","journal-title":"J Virol"},{"issue":"7","key":"5158_CR210","doi-asserted-by":"publisher","first-page":"3792","DOI":"10.1128\/jvi.78.7.3792-3796.2004","volume":"78","author":"E Moreau","year":"2004","unstructured":"Moreau E, Hoebeke J, Zagury D, Muller S, Desgranges C (2004) Generation and characterization of neutralizing human monoclonal antibodies against human immunodeficiency virus type 1 Tat antigen. J Virol 78(7):3792\u20136. https:\/\/doi.org\/10.1128\/jvi.78.7.3792-3796.2004","journal-title":"J Virol"},{"issue":"15","key":"5158_CR211","doi-asserted-by":"publisher","first-page":"11942","DOI":"10.1074\/jbc.M111.319863","volume":"287","author":"S Mediouni","year":"2012","unstructured":"Mediouni S, Watkins JD, Pierres M, Bole A, Loret EP, Baillat G (2012) A monoclonal antibody directed against a conformational epitope of the HIV-1 trans-activator (Tat) protein neutralizes cross-clade. J Biol Chem 287(15):11942\u201350. https:\/\/doi.org\/10.1074\/jbc.M111.319863","journal-title":"J Biol Chem"}],"container-title":["Archives of Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00705-021-05158-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00705-021-05158-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00705-021-05158-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T10:00:10Z","timestamp":1744192810000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00705-021-05158-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,14]]},"references-count":211,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["5158"],"URL":"https:\/\/doi.org\/10.1007\/s00705-021-05158-z","relation":{},"ISSN":["0304-8608","1432-8798"],"issn-type":[{"value":"0304-8608","type":"print"},{"value":"1432-8798","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,14]]},"assertion":[{"value":"14 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 May 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflict of interest. The funders had no role in the conceptualization of the study, in the collection, analysis or interpretation of data, in the writing of the manuscript, or in the decision to publish the results.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}